annual report year ended march song real growth company policy shionogi shionogis purpose shionogi strives constantly supply best possible medicine protect health wellbeing patient serve purpose shionogi need pursue search even better medicine produce even better medicine promote awareness better medicine people people able use medicine research produce promote even economical manner purpose shionogi people need strive ceaselessly day day improve skill strive ceaselessly day day improve human result shionogi people find even greater satisfaction daily work daily life find even greater improvement quality life find even greater prosperity life established shionogis action guideline mission vision value mission deliver pharmaceutical offer even higher level satisfaction patient family healthcare provider improve quality life patient family vision company strong presence worldwide company pride dream embrace challenge value customer focus trust professionalism onsite orientation respect individual content management management shionogis year history stakeholder snapshot performance highlight interview president shionogis business shionogis business activity activity research development sale overseas business activity manufacturing editorial policy pipeline period review major product fiscal april march certain activity continuing fiscal also included scope organization shionogis csr shionogis csr activity annual report encompasses activity shionogi co ltd activity fundamental policy csr company consolidated subsidiary affiliate section entitled effort preserve environment cover community relation business facility shionogi co ltd six domestic subsidiar relationship employee report shionogi refers shionogi co ltd onsite subsidiary effort preserve environment domestic subsidiary refers one domestic manufacturing subsidiary shionogi pharma chemical co ltd two domestic nonmanufacturing subsidiary shionogi general service co ltd saishin igaku co ltd shionogi group refers aforemen management management system tioned company system corporate governance note concerning numerical value graph member board numerical value rounded nearest unit applicable total may match due rounding financial financial section forwardlooking statement section tenyear consolidated financial highlight report contains forwardlooking statement statement management discussion analysis based expectation light information currently available assumption subject risk uncertainty could business risk cause actual result differ materially statement risk uncertainty include general domestic international consolidated financial statement economic condition general industry market condition change interest rate currency exchange rate risk uncertainty particularly apply forwardlooking corporate corporate information statement concerning existing product development product risk uncertainty include limited comple information shionogi group directory tion discontinuation clinical trial obtaining regulatory approval claim concern product safety efficacy technological corporate information advance adverse outcome important litigation domestic foreign healthcare reform change law regulation existing product also manufacturing marketing risk include limited inability build production capacity meet demand unavailability raw material competi tion company product company disclaims intention obligation update revise forwardlooking statement whether result new information future event otherwise report contains information pharmaceutical including compound development information intended make representation advertisement regarding efficacy pharmaceutical provide medical advice kind shionogi annual report shionogis business activity shionogis csr activity management system financial section corporate information management shionogis year history shionogi positioned fiscal first year group globalization based tradition history stretching back year company foundation shionogi looking realize company policyto strive constantly supply best possi ble medicine protect health wellbeing patient serveon global basis gisaburo shiono sr founder corporate emblem fundoh company policy shionogi company launched shiono gisaburo registered established shoten drug wholesaler present site head office fundoh mean pursue taiwan shionogi co ltd doshomachi osaka truth established shionogis corporate emblem founder derived fundoh weight used measure established settsu plant gisaburo shiono sr medicine balance sym bolizes accuracy honesty gisaburo shiono sr established developmental research trust express born doshomachi laboratory shionogi pharmaceutical shionogis wish constant osaka guidance research center sprc pursuit truth father kichibe learned wholesale trade march fundoh edo era constructed kanegasaki plant launched drug wholesaling business doshomachi th launched cephem antibiotic flomox antacidin antacid agent launched birthday wholesaler predecessor first drug produced established shionogi charter shionogi co ltd conduct manufacturing plant shiono seiyakusho constructed management shionogi decided con centrate imported western drug shiono gisaburo shoten shiono seiyakusho merged new company named shionogi shoten co ltd shionogi started deal directly trading firm europe u established kuise plant kuise site company renamed shionogi seiyaku kk shionogi co ltd developed aburahi laboratory aburahi facility shionogi annual report shionogi limited uk co pharmaceutical shionogi inc development foothold eu technology holding limited development manufacturing sale rd manufacturing sale pharmaceutical u pharmaceutical china first mediumterm second mediumterm third mediumterm business plan start business plan start business plan start laying foundation accelerating toward significant stride song real growth completion corporate restructuring established constant flow pipeline product launch multiple product developed concentrate pharmaceutical business energizing globalizing rd globally real growth launched hyperlipidemia treatment crestor launched antiviral drug influenza launched carbapenem antibiotic finibax rapiacta established shionogi usa inc sold bushu pharmaceutical ltd contract shionogi inc manufacturing company transferred agricultural chemical business launched cancer pain analgesic oxinorm launched antidepressant drug cymbalta established joint venture named shionogi established pet molecular imaging glaxosmithkline pharmaceutical llc established shionogi analysis center co ltd center osaka university graduate shionogiviiv healthcare llc school medicine launched hypertension treatment irbetan started joint research development established shionogi inc u established joint research facility hok including hiv integrase inhibitor group headquarters kaido university shionogi innovation center drug discovery established shionogi techno advance transferred veterinary drug business acquired sciele pharma inc research co ltd clinical laboratory shionogi inc sold ohmori co ltd wholesaler launched acne vulgaris treatment differin completed new research facility sprc pharmaceutical launched idiopathic pulmonary fibrosis acquired chinese pharmaceutical treatment pirespa company co pharmaceutical th launched cancer pain analgesic oxycontin technology holding limited established ezose science inc venture com pany providing serum glycan analysis service established european subsidiary shionogi limited launched injectable cancer pain analgesic oxifast revised hiv integrase inhibitor relationship viiv launched postmenopausal vulvar vaginal atrophy treatment osphenatm shionogi annual report shionogis business activity shionogis csr activity management system financial section corporate information management stakeholder shionogi group pushing ahead third mediumterm business plan aim achieving growth medium long term shionogi group midst implementing third mediumterm business plan spanning period fiscal fiscal plan designed enable shionogi group overcome crestor cliff phrase refers expected drop royalty income resulting expiration patent hyperlipidemia treatment crestor mainstay product continue grow royalty income thereafter working hard bring innovative new drug market globally expand earnings realize medium longterm vision fiscal management target fiscal aim consolidated net sale billion consolidated net sale billion operating income billion operating margin least overseas net sale billion overseas net sale ratio least president ceo chairman board shionogi annual report fiscal halfway point business plan year many accomplishment fiscal year ended march secured stable earnings japanese market absorbing impact nhi drug price revision steady growth eight strategic product particularly new drug overseas market stable operation produced improved profitability u subsidiary shionogi inc chinese subsidiary co made first fullyear contribution net sale thus making steady progress solidifying base shionogi group grow globally fiscal significant year term development compound underpin future growth antihiv drug october entered agreement substantially revised inte grase inhibitor relationship ukbased development partner viiv clarified future earnings prospect december viiv filed new drug application nda u eu canada anti hiv agent dolutegravir generic name expects gain approval launch drug u summer whats treatment postmenopausal vulvar vaginal atrophy osphenatm ospemifene gained regulatory approval u february launched following june compound latestage clinical development global basis also made steady progress earnings front part effort improve earnings structure ahead crestor cliff worked reduce cost even across company result effort income level higher level prior fiscal year working ensure achieve business plan target fiscal stepping globalization grow crestor cliff aim secure stable earnings japan mother market time continuously launch proprietary product subsidiary u world largest pharmaceutical market fastgrowing chinese market grow steadily global basis term research development addition priority therapeutic area metabolic syndrome take challenge research new therapeutic area high unmet medical need including central nervous system disorder determined quickly develop future growth driver globally also utilizing uk subsidiary shionogi group work one steadily execute basic strategy third mediumterm busi ness plan meet demand society develop continuously way realize company policy shionogi globally deliver tangible benefit growth stakeholder look ward receiving ongoing support guidance stakeholder co pharmaceutical technology holding limited viiv healthcare ltd refers condition remains satisfactory method treatment shionogi annual report shionogis business activity shionogis csr activity management system financial section corporate information management snapshot shionogi medium longterm vision overcome socalled crestor cliff fiscal enter era renewed growth era renewed growth fiscal aim consolidated net sale billion domestic net sale operating margin overseas net sale least fiscal crestor royalty plan overseas net sale ratio others net sale least billion fiscal forecast net sale crestor cliff expected drop royalty income resulting billion expiration fiscal patent crestor net sale leading product billion fiscal net sale billion global development nurture future growth driver compound cancer vaccine etc global hiv grow antihiv agent integrase inhibitor royalty income dividend viiv healthcare global new product grow new drug osphenatm overseas sale expansion domestic grow eight strategic product strategy solidify domestic marketing base three basic strategy third mediumterm steady growth mainly enriched pipeline fourth mediumterm business plan investment new growth driver business plan yet announced therapeutic area focused shionogi annual report fiscal achievement global new drug treatment postmenopausal vulvar vaginal atrophy osphenatm ospemifene filed regulatory approval obtained regulatory please refer u april approval page february filed regulatory approval launched june eu march global antihiv agent dolutegravir integrase inhibitor global antihiv substantially revised integrase inhibitor relationship agent market please refer viiv october approx page us billion filed regulatory approval u canada eu fy december source evaluate pharma global latestage clinical development product phase phase ii alleviation opioidinduced adverse effect compound compound please refer started phase iii clinical trial globally page allergic rhinitis treatment phase iii submission approval phase iii lpo seasonal allergy japan last patient compound compound august eight strategic product japan net sale share sale billion yen fy fy fy steadily expanding sale please refer page increased share prescription drug sale japan prescription drug sale japan cost management operating income billion yen achieved record operating income fy fy fy appropriately efficiently controlled expense shionogi annual report shionogis business activity shionogis csr activity management system financial section corporate information management performance highlight thousand million yen u dollars fy fy fy fy fy fy year ended march net sale cost sale selling general administrative expense operating income income income tax minority interest net income research development expense capital investment depreciation amortization net cash provided operating activity net cash used investing activity march property plant equipment net total asset total longterm liability total net asset per share amount yen u dollar net income net asset dividend equity ratio return equity roe return asset roa payout ratio nonfinancial data co emission thousand ton co amount waste generated ratio hybrid electric vehicle u dollar figure calculated convenience rate us approximate rate exchange march electric power co conversion u internally specified figure data fiscal change scope aggregation following enforcement amended act temporary measure promotion rational u energy recycled resource excludes cold region japan shionogi annual report net sale overseas net sale ratio operating income net income net income ratio operating income ratio billion yen billion yen billion yen billion point billion point billion point fy fy fy net sale operating income net income overseas net sale ratio operating income ratio net income ratio research development expense roe roa dividend per share payout ratio research development expense ratio billion yen yen billion yen fy fy fy research development expense roe dividend per share research development expense ratio roa payout ratio point reflects sluggish performance u business point reflects extraordinary loss including loss disaster attributable great east japan earthquake business structure improvement expense impairment loss u operation point reflects lower tax expense due impairment loss valuation stock affiliate nonconsolidated basis associated revaluation u operation stock data yen shionogi annual report shionogis business activity shionogis csr activity management system financial section corporate information management interview president president ceo isao teshirogi phd shionogi annual report shionogi positioned fiscal first year group globalization work course year toward realizing company policy globally wake realignment within domestic pharmaceutical industry consequence widespread activityand multinational drugmakers pushing deeper japanese market shionogi group established development sale base u europe asia view ensuring ongoing steady independent growth rdoriented global pharmaceutical company result effort poised move onto higher growth trajectory fiscal group whole clarify priority determining cost allocation putting highest priority new product launched u market mean growing overseas sale identified fiscal first year shionogis globalization also seek plant domestic employee realization shionogi global company requiring adopt much broader mindset continuous global development breakthrough new drug required shionogi group survive fierce competition overcome crestor cliff occur achieve growth postcrestor era end employee working one realize shionogi company policy globally spirit striving con stantly ensure patient around world access best new drug soon humanly possible shionogi annual report shionogis business activity shionogis csr activity management system financial section corporate information management interview president question first could outline initiative taken globalize operation mean overcoming crestor cliff describe result seen fiscal domestic prescription pharmaceutical market expected expand going ward shionogi must pursue significant presence large u european market well china emerging economy expected experience high growth ever must apply global perspective determining best utilize group limited resource term manpower good capital order maximize value pipeline product bringing market quickly essential make timely decision product prioritize market whether best case go alone develop product jointly another company alternatively secure licensing agree ment sense fiscal important year term laying groundwork globalization shionogi group revised agreement viiv healthcare concerning antihiv drug believe evolve key pillar earnings october restructured agreement ukbased pharmaceutical company viiv healthcare partner joint development antihiv drug hope become important source income shionogi group revision concern sale right management operation amended agreement continue say management shareholder viiv addition receiving royalty fixed percentage sale dividend viiv believe change allow u dedicate resource development sale proprietary global product antihiv agent dolutegravir granted priority review status fda expect approval launch take place summer fda u food drug administration shionogi annual report strategy surmounting crestor cliff relationship viiv concerning antihiv drug n right dolutegravir hiv integrase inhibitor franchise product shionogi transferred viiv shionogi becoming shareholder viiv gsk pfizer co ltd japan n receive dividend viiv proportionate shareholding also entitled representation viivs board one person n receive royalty averaging high teen sale dolutegravir shionogi ltd franchise product uk shareholding principle amout decline even combination preparation merit new framework viiv group representation viivs board shionogi say management uk make ongoing contribution maximizing value dolute gravir franchise product thereby augmenting royalty income jv resource previously used integrase inhibitor development chan neled rd internally developed product achieve early global launch growth driver succeed dolutegravir antihiv drug market hiv infected people approx million source unicef unaids progressive report antihiv market approx us billion source evaluatepharma yearonyear increase regional breakdown u approx country approx profile dolutegravir dolutegravir nextgeneration hiv integrase inhibitor jointly developed shionogi viiv discovered joint research shionogi glaxosmithkline plc n viiv filed ndas u europe canada december n fda granted priority review designation n product profile high degree clinical activity phase iii trial conducted treatmentnaive patient approximately patient dolutegravir group maintained viral load less copy per ml week data unlikely produce drugresistant virus treatmentnaive patient observation dolutegravir producing virus resistant either dolutegra vir drug used combination background therapy low crossresistance also effective patient failed therapy using existing integrase inhibitor good pharmacokinetics taken daily without need pharmacokinetic booster administered together antihiv drug without need dose adjustment integrase inhibitor block hiv replication inside body preventing viral dna integrating genetic material human immune cell jv previous agreement shionogi held right global hiv aid response report issued world health organization united nation childrens fund unicef joint united nation programme hiv aid unaids used combination maintain improve drug antiviral effect maintaining sufficient drug concentration blood drugmetabolizing enzyme inhibition shionogi annual report shionogis business activity shionogis csr activity management system financial section corporate information management interview president launched osphenatm u shionogi group first global drug june saw launch u world largest pharmaceutical market shionogi group first global drug osphenatm treatment postmenopausal vulvar vaginal atro phy vva right entire group top priority quickly maximize value osphenatm believe significant role play improving patient qol quality life fiscal group strive one increase sale osphenatm u market march also submitted marketing authorization application maa european medicine agency ema process selecting commercialization partner eu hope also quickly deliver drug patient suffering vva europe well contribute treatment believe aforementioned change agreement viiv regarding antihiv drug u launch global product osphenatm development paved way shionogi overcome crestor cliff grow operation also working enrich accelerate development pipeline secure growth driver two product eye enhancing development efficiency shionogi strengthen global portfolio management redoubling effort develop market proprietary medicine across entire networkin japan u europe also china osphenatm launched june shionogi annual report strategy surmounting crestor cliff global drug osphenatm osphenatm provides new treatment option many woman troubled dyspareunia painful intercourse due menopause approximately million postmenopausal woman u experience symptom vva around million treated prescription medication seems majority woman vva treated woman doctor proactively discussing condition symptom postmenopausal vulvar vaginal atrophy vva market u woman population million x postmenopausal year million x population woman vva million x unmet medical need estimate vvadiagnosed patient million woman arent treated x prescription drug patient treated prescription drug million n product profile osphenatm estrogen agonist antagonist tissue selective effect first oral alternative existing vaginal estrogen bind estrogen receptor resulting activation estro genic pathway tissue agonism blockade estrogenic pathway others antagonism clinical trial confirmed efficacy safety osphenatm demonstrated significant improvement dyspareunia relative placebo form increase propor tion superficial cell decrease proportion parabasal cell reduction vaginal ph n schedule eu submitted maa march asia consideration shionogi annual report shionogis business activity shionogis csr activity management system financial section corporate information management interview president question please discus global development compound believe function new growth driver alongside dolutegravir osphenatm pipeline includes number product believe hold key shionogis future growth among cancer peptide vaccine latestage development compound alleviation constipation opioidinduced adverse effect allergic rhinitis treatment furthermore october expanded offering one core therapeutic area entering license agreement kotobuki pharmaceutical co ltd hypercholesterolemia treatment different mechanism action crestor month inked agreement usbased janssen pharmaceutical inc aimed speeding development maximizing value drug candidate sphere alzheimers disease treatment thereby enhancing contribution patient worldwide term contract drug candidate alzheimers disease discovered shionogi employing new mechanism action licensed janssen wealth experi ence expertise development therapeatic area rd promotion collaboration japanese international university research institution contributed already discovery innovative new drug candidate also significant think vva treatment osphenatm secured fda approval schedule favorable condition era new drug obstetrics gynecology fre quently knocked back source pride regard testament shionogi group improved development prowess shionogi continue striving bring revolution ary new product patient around world soon humanly possible maintaining cre dentials rdoriented global pharmaceutical company keeping rd expenditure around consolidated sale clearly defining priority assigned individual compound prescription narcotic shionogi annual report treatment alleviating opioidinduced adverse effect generic name naldemedine n feature oral medication minimal cns effect selectively target peripheral opioid recep tor therefore effectively alleviating opioidinduced adverse effect including constipation nausea vomiting exerting adverse impact analgesic effect opioids n result clinical trial date verified relief opioidinduced constipation oic evidence central opioid withdrawal change pain intensity opioid dosage oncedaily administration generally well tolerated favorable pharmacokinetics low interindividual variability dosedependent exposure n development stage global conducted end phase ii meeting fda started phase iii clinical trial japan preparing start phase iii clinical trial allergic rhinitis treatment n feature combination therapy antihistamine show remarkable suppressive effect vari ous symptom allergic rhinitis surpassing existing oral antiallergy agent demonstrated possibility replacing steroid nasal spray new oral treatment n result clinical trial date among dp receptor antagonist first world demonstrate clinical efficacy allergic rhinitis effective given daily demonstrated good tolerance safety n development stage japan conducting phase iii clinical trial seasonal allergic rhinitis started phase iii clinical trial perennial allergic rhinitis europe completed pom proof mechanism study u conducted phase iia clinical trial one prostaglandin receptor shionogi annual report shionogis business activity shionogis csr activity management system financial section corporate information management interview president question please describe current state future outlook chinese business china pharmaceutical market track overtake japan second largest world co pharmaceutical technology holding limited co subsidiary since shionogi group used many year experience promoting proper use drug infectious disease japan garner greater share chinese market principally antibiotic unfortunately however shionogis drug still sufficiently reached chinese patient aim steadily grow shionogi group china sale medium long term process make greater contribution medical care china achieved co develop launch new shionogibrand product also promote research development collaboration chinese academic center excellence largely beijing shionogi phar maceutical technology limited another china subsidiary launched june overview beijing shionogi pharmaceutical technology limited company name beijing shionogi pharmaceutical technology limited representative masaaki takeyasu head office room level tower china central place jianguo road chaoyang district beijing date establishment march capital million business description technical support clinical development sale marketing information consulting question intention restructuring group production supply chain organization april undertook organizational change aimed improving accuracy global production setup supply chain management scm work ensure stable supply highquality product globally promoting greater collaboration manufacturing divi sion newly created global scm division optimizing operation reducing cost sale global manufacturing management system spanning production strategy planning procurement manufacturing inventory control new approach scm got first test june u launch new vva treatment osphenatm shionogi annual report question finally please discus initiative planned increase corporate value shareholder return medium long term shionogi group basic policy profit distribution maintain stable dividend share holder taking account capital demand future business development profit earned relevant fiscal period among company major achievement fiscal revision alliance viiv concerning development antihiv drug believe new scheme clarifies future earnings prospect dolutegravirwhich expect attain blockbuster statusand franchise product believe u launch osphenatm treatment vva succeeded stabilizing longerterm outlook overseas operation enhancing prospect growth event end fiscal shionogi increased consolidated dividend payout ratio target return profit shareholder based new dividend policy shionogi raise yearend cash dividend fiscal per share together interim cash dividend therefore pay annual cash dividend per share shionogi group continue proactively undertake business activity eye enhancing corporate value longerterm objective steadily increase return deliv ered shareholder dividend per share payout ratio yen dividend per share payout ratio yen yen fy forecast dividend policy shionogi aim raise dividend steadily line performance consolidated dividend payout ratio target consolidated payout ratio approx based net income excluding onetime positive effect tax expense shionogi annual report management shionogis business shionogis csr activity management system financial section corporate information activity research fiscal achievement fiscal target saving patient worldwide proprietary innovative new drug fiscal shionogi reached final step supply patient worldwide anti hiv agent dolutegravir drug created jointly uk glaxosmithkline plc phase iii clinical trial proven significantly effective existing treatment also advanced proprietary drug proprietary drug candidate allergic rhinitis proprietary drug candidate alleviating opioidinduced adverse effect latestage clinical trial nearing goal helping patient around world groundbreaking new drug developed internally furthermore number alzheimers disease patient increasing background aging corporate officer senior vice president society shionogi also licensed drug candidate belonging class known bace pharmaceutical research division inhibitors janssen pharmaceutical inc u time also entered kohji hanasaki phd research collaboration discovery backup compound delivering advance small molecule drug discoveryan area existing expertiseshionogi also expanding aggressively large molecule pharmaceutical area output third mediumterm business plan target drug candidate includes antipseudomonas aeruginosa antibody developed inhouse cancer peptide vaccine inlicensed oncotherapy science inc moreover shionogi focusing effort accelerating rd activity field oligonucleotide drugs including antisense decoy nucleic acid alliance following three area enhancement early phase researchportfolio new drug creation hinge innovation improvement predictive perfor shionogis third mediumterm business plan pharmaceutical research division mance clinical efficacy cen committed searching groundbreaking drug discovery seed improving predic tralization function tive performance clinical efficacy search drug discovery seed shion strengthening flexibility ogi early adopter domestically overseas open innovation industry set two numerical performance academia uncover academic research seed matching company research need thus far collaboration included find ssp flash target first select four strengthen effort identify mature novel seed joint research new molecular entity nmes industry academia fiscal expanded ssp program include australia drug candidate selection per year belgium denmark luxembourg netherlands addition uk second create nmes bid improve predictive performance clinical efficacy continue success rate engage research molecular imaging technology pet molecular imaging poc study center osaka university graduate school medicine using internally devel oped pet imaging probe confirmed nonclinical efficacy central nervous system cns compound development preparing framework manufacture pet imaging formulation gmp well entering prepara tions microdosing clinical study collaboration osaka university hospital collaborative research ip cell undertaken shionogi innovation center ground hokkaido university stage utilizing ip cell research cns disease assay method would correlate clinical event march entered comprehensive collaboration agreement medical innovation center kyoto university graduate school medicine agreement kyoto university shionogi collaborate create innovative medicine treatment alzheimers disease cns disorder seeking meet critical unmet medical need basic research regarding underlying pathology thereby finding new drug target regeneration synapsis neuronal function collab oration also promote training development academic industrial scien tists medicine drug discovery research shionogi annual report voice frontline help realize goal outlined shionogis third mediumterm business plan pharmaceutical research division also using shionogi pharmaceutical research center engage collaborative research shionogi techno advance research co ltd star shanghai sunsail pharmaceutical science technology co ltd research subsidiary chinese company co pharmaceutical technology holding lim ited remaining active researchdriven pharmaceutical company strive con stantly improve science productivity relationship creativity better realize company policy global perspective creating providing new medicine medicinal research laboratory eagerly awaited patient shionogi family worldwide takashi kawasuji poc study human clinical trial designed demonstrate early sign product efficacy proof concept shionogis antihiv drug research team drug block activity betasecretase enzyme needed generation betaamyloid protein comprises member varying specialty substance identified causing alzheimers disease drug composed nucleotide dna rna act directly gene protein known cause disease working one pursue drug discovery find domestic drug discovery competition pharmainnovation discovery competition shionogi research pursuit company ssp overseas drug discovery competition shionogi science program flash drug discovery initiative osaka university graduate school medicine pharmalink goal year tire academia shionogi less search better compound standard quality control production management quasidrugs pharmaceutical product good often verge collapse variously manufacturing practice employing cuttingedge science wealth creativity firm resolve upshot work dolutegravir many people worked feverishly development drug intellectual property start supply shionogi group global intellectual property strategy forged close link ing patient pleasure rd strategy business strategy also provides support alliance able real thrill drug activity patent protection marketed pipeline product discovery research case research development company work reserve suitable patent prime motivation right development compound substance drug discovery target basic research technology also maximizing patent protection period protect ing patent revenue efficiently obtaining patent regarding indication crystalline form manufacturing method formulation activity shionogi filed approximately patent application fiscal filed overseas eye growth emerging market company stepped patent filing country company periodically review patent portfolio taking cost account march shionogi held approximately patent japan patent family overseas part business strategy company take every care conduct intel lectual property due diligence inlicensing outlicensing product ward potential patent infringement shionogi also engaged brand design activity mean reliability assurance company product combating counterfeiting fiscal company filed application trademark registration application design registration evolution pharmaceutical manufacturer shionogi continue working one implement intellectual creation cyclewhich creates pro tects generates earnings intellectual property shionogi annual report management shionogis business shionogis csr activity management system financial section corporate information activity development fiscal achievement fiscal target two major achievement fiscal saw shionogi chalk two major achievement one obtaining regula tory approval first new chemical entity filed shionogi u filing new drug application u europe canada april shionogi filed new drug application u selective estro gen receptor modulator osphenatm generic name ospemifene regulatory approval received scheduled february furthermore shionogi filed regulatory approval europe march shionogi developing antihiv agent dolutegravir jointly viiv senior executive officer senior vice president global development healthcare ltd october shionogi acquired share viiv revised royalty pharmaceutical development division agreement time transferred development right viiv december takuko sawada new drug application submitted u food drug administration fda european medicine agency ema canada planned third mediumterm business plan mission accelerating global development two latestage drug currently two global product latestage clinical development shionogi endeavoring enhance alleviation opioidinduced adverse effect treatment development function worldwide allergic rhinitis started phase iii clinical study globally based result end phase ii meeting held february fda time unify clinical trial conducted japan u europe global clinical development strategy japan highest unmet medical need regard hay fever treatment phase specific target third iii trial conducted advance country going forward aim mediumterm business plan accelerate global development prioritizing resource two product make submission overseas regulatory approval four com maximizing rich pipeline pound originating shionogi also japan promoting multiple latestage development including throm bocytopenia treatment attention deficit hyperactivity disorder adhd drug japanese research institute well duloxetine additional indication fibromyalgia chronic low back launch one product pain oxycodone additional indication noncancer pain globally develop taking phase iii clinical trial several compound developed domestically five latestage product shionogi overseas aim quickly supply drug outside latestage development program also working next global market generation therapy form cancer peptide vaccine antibody drug looking ahead shionogi seek identify select development compound even earlier stage prioritizing rd expense compound also exploring partnership outlicensing inlicensing opportunity view getting wealth development asset see page pipeline list compound shionogi annual report voice frontline target milestone fy global development compound name indication progress target alleviation opioid global phase iii initiation induced adverse effect allergic rhinitis u eu phase ii completion bladder cancer eu poc initiation malignant tumor eu phase ii initiation bacterial infection u phase ii initiation inflammatory pain u phase ii initiation global development office neuropathic pain u pom initiation tamio fujiwara target milestone fy domestic development pharmaceutical development involves compound name indication progress target cymbalta chronic low back pain phase iii initiation teamwork great pleasure alleviation opioid utilize team member opinion formu phase iii initiation induced adverse effect lating development strategy allergic rhinitis phase iii codebreak seasonal allergic rhinitis creating protocol report academic thrombocytopenia phase iib codebreak go nogo decision presentation based individual clinical obesity phase iib codebreak go nogo decision dyslipidemia phase iib codebreak go nogo decision nonclinical trial ultimately allergic rhinitis caused creates highquality package illus phase ii iii codebreak housedust mite allergen trates compound characteristic agerelated macular best possible light whole phar phase iia codebreak go nogo decision degeneration bladder cancer poc initiation maceutical development full chal inflammatory pain phase ii initiation lenges regarding clinical science fivepeptide cocktail vaccine requires scientific logical thinking proof mechanism data thus generated keep stim ulated excitement anticipation day another shion shionogi limited ogi baby come world uk subsidiary shionogi limited established february promote pharmaceutical devel opment industryacademic collaboration europe well follow hta establishment acceptance trend worldwide aim incor porating finding development plan march shionogi limited submitted market ing authorisation application maa ospemifene via combination inhouse sale ceo partnering subsidiary working toward achieving development sale objective takashi takenoshita mediumterm business plan eu shionogi science program initiated uk fiscal col laborative industryacademia initiative expanded scope include country promoting collaboration european academia joint effort shionogis pharmaceutical research division innova tion design office health technology assessment shionogi annual report management shionogis business shionogis csr activity management system financial section corporate information activity sale fiscal achievement fiscal target expanded market share strategic product making progress drive create earnings structure dependent longlisted drug domestic sale shionogi focusing expanding sale strategic product executes one basic strategy third mediumterm business plan namely steady growth mainly enriched pipeline fiscal shionogi launched aimix irbetan family product oxifast oxycontin family product well added indication cymbalta fini executive officer bax thereby raising shionogis presence priority market cardiovascular senior vice president metabolic disorder pain infectious disease human health care division result fiscal sale crestor rose year year billion sale ryuichi kume phd irbetan family product climbed billion sale cymbalta leapt billion lifted sale strategic product year year billion third mediumterm business plan mission steadily executing basic strategy new organization fiscal aim achieve anticipate change business climate including hike consumption net sale japan billion tax rate measure promote increased uptake generic drug revision increase combined sale japan healthcare system elderly order better deal change still implementing basic strategy third mediumterm business plan strategic product least undertaken organizational reform following carried total domestic sale begin simplified organizational structure create wellbalanced mar keting mix cs customer value customer cost convenience communication view removing barrier top management frontline employee sought create even flatter organizational structure also improved educa tion training support medical representative mr order provide medical professional even betterquality product information fiscal shionogi augmenting lineup treatment cardiovascu lar metabolic disorder launch metreleptin well launch irbetan mg soontobelaunched irtra irbetan family drug line first basic strategy view achieving mediumterm objective pursue sale activity particular focus new product voice conversation healthcare professional endeavor listen attentively description patient concern learned individual see frontline patient disease attentiveness affords u thorough understanding various difficulty besetting patient healthcare professional enabling u offer customer solution built around shionogi product recently oncologist told patient suffering skin complaint due adverse reaction cancer treatment suggested therapy shionogi product grateful behalf company mr glad service patient continue giving pharmaceutical promotion department hope receiving word thanks many healthcare professional rie koyama shionogi annual report overseas business activity fiscal achievement fiscal target u operation fiscal achieved performance target via raft reform aimed stabi lizing management shionogi inc strengthening operation developing highly profitable business structure effective utilization human resource received fda approval february launched osphenatm june treatment postmenopausal vulvar vaginal atrophy vva condition thought affect million woman u among shionogi group global product osphenatm first win regulatory approval u took companywide effort looking ahead plan grow womens health new fran corporate officer senior vice president chise view expanding scope operation osphenatm differ overseas business division ent mechanism action traditional estrogenalone therapy task masaaki takeyasu fiscal utilize academic activity garner swift recognition among wom en health specialist drug efficacy safety also proactive undertaking directtoconsumer educational campaign encouraging woman broach third mediumterm business plan mission doctor sensitive subject painful intercourse due postmenopausal vva working create new market treatment also fit womens life overseas business division style contribute improved qol established january china taiwan operation mission delivering shionogi since china actively promoting responsible use antibiotic via new product huge potential administrative regulation governing clinical use antibacterial agent shionogi medical professional prior experience japan academic activity focused proper use antibiotic patient around world treating infectious disease provided co ample support respect end overseas business division bolster support academic activity june shionogi established soundly operating subsidiary local subsidiary beijing promote collaboration chinese academia globally absence new drug control infectious disease urgent issue u china taiwan well strive help many patient possible collaborating academic china exporting product taiwan asian nation promote rational use existing antibiotic deemed potential treating resistant bacteriaa scourge know border company policy shionogi espouses universal truth raison detre pharmaceutical company release osphenatm designated fiscal first year shionogis globalization company continue search unmet medical need europe asia elsewhere operating highquality business around world order fulfill social mission pharmaceutical manufacturer launch meeting osphenatm shionogi annual report management shionogis business shionogis csr activity management system financial section corporate information activity overseas business activity shionogi inc fiscal achievement fiscal target fiscal year significant progress shionogi inc achieved financial target realized six consecutive quarter ontarget financial perfor mance give u solid stable base build going forward initiative expanding osphenatm fiscal important event shionogi inc impending launch osphenatm firstin class oral drug treatment dyspareunia painful intercourse symptom vulvar vaginal atro shionogi inc phy vva due menopause approved fda february osphenatm represents first president ceo new chemical entity ever filed approved launched shionogi u year history john keller phd estimated million woman u experiencing symptom vva treated prescription medicine tremendous opportunity make difference patient establish innovative new entrant underserved area womens health osphenatms launch also represents turning point shionogi inc become major contributor shionogis global growth began fiscal therefore intensively preparing launch finalizing plan strengthening training sale force osphenatm also begun outreach womens health group expressed strong interest new therapy effort develop next proprietary drug osphenatm even given excitement osphenatm lost focus numerous clinical study initiating progressing u development shionogidiscovered pipeline perhaps important amongst initiation phase iii pivotal study naldemedine treatment opioidinduced constipation successful naldemedine succeed osphenatms first becoming first internally discovered new chemical entity launched shionogi u role corporate officer shionogi co ltd deeply honored named corporate officer shionogi co ltd reflec tion fully realize progress made u truly result dedicated team effort across global shionogi family whose member work intensively creatively advance pipeline support business together improve patient health quality life thus realize shionogis mission every day hope able contribute success shionogi co ltd globally within beyond shionogi inc voice work colleague successfully launch osphenatm u reflect back incredi ble collaboration global shionogi partner enabled shionogi inc reach mile frontline stone well nda filing clinical pharmacology reviewed accuracy pharmacokinetic data designed analyzed bioequivalence study one particular pivotal led nda filing nonclinical colleague ensured availability quality nonclinical senior director medical data required nda submission biostatistics group provided highquality timely review affairswomans health nda data package ran additional analysis support filing finally cmc worked shelli graham shionogi inc fully characterize osphenatm utilizing long history rd optimize production product group also played critical role responding question fda ultimately facilitated ontime approval osphenatm proud energized part team greatest hope collabo rative precedent set development osphenatm become model going forward maximizing global opportunity osphenatm pipeline product follow shionogi annual report co mission co integrated pharmaceutical company engaged rd manufacturing distribution prescrip tion pharmaceutical product china employee across fastgrowing chinese market operate basic philosophy wishing long life creating brilliant future hand hand company mainstay product antibiotic spearheaded flumarin amolin amoxicillin china regulating use antibiotic co view change business climate opportunity growth conjunction parent company co continue provide customer appropri executive vice president ate information shionogi product view garnering greater market share also working masaki tomiyama toward early release doripenem time focus rd geared toward launch product discovered internally striv ing bring forward day roll first product originated co thereby improving life still patient realize shionogi company policy chinanamely striving constantly supply best possible medicine protect health wellbeing patient serveco redouble effort develop proprietary new drug also pursuing collaboration shionogi group company voice although co joined shionogi family employee secure belief helping advance company policy shionogi wealth experience frontline rdoriented pharmaceutical company many year standing member shionogi family co course committed upholding shionogi company policy striving constantly supply best possible medicine protect health wellbe executive vice president ing patient serve concomitantly aim build greater presence china enormous pharmaceutical market xu yan taiwan shionogi co ltds mission taiwan shionogi approaching th anniversary manner shionogi company pledged supply best possible medicine improve health wellbeing patient taiwan cur rently taiwan shionogi around mr providing information company product special focus infectious disease company mainstay product antibiotic flumarin finibax flumarin currently ranking taiwan topselling injectable cephem antibiotic taiwan shionogi also preparing domestic launch rapiacta pirespa product already marketed japan field infec tious disease particular company remain actively engaged new drug development inlicensing president ceo taiwan shionogis marketing sale team rival parent term nationwide coverage com masami morita pany primary mission improve health patient taiwan beyond aim contrib ute shionogis business expansion asia bolstering human resource development building effective organization also entering partnership pharmaceutical company voice shionogis company policy built upon focus customer believe concept principle profit one universally accepted taiwan shionogi longest frontline history overseas base within shionogi group fully understands executes shionogi corporate philosophy take pride belief taiwan shionogis marketing sale team surpasses company capacity disseminate information general manager together local staff approach job every day conviction shionogi accounting department acting interest taiwanese patient relish able kenji kuroda shionogi annual report management shionogis business shionogis csr activity management system financial section corporate information activity manufacturing third mediumterm business plan mission shionogi implementing global quality assurance system basic goal strengthening production system ensuring stable supply support global launch inhouse product way shionogi harness ing strength ensure quality safety reliability shionogi brand mission collaboration organization new structure shionogis new division redoubling collaborative effort related organization also working ensure stable supply support timely global launch newly developed product improvement quality manufacturing division mission strengthen company quality maximizing manufacturing division primary mission ensure cash flow across group achieve create strong stable supply highquality product low cost prod partnership division involved flow supplier uct safety quality foremost priority customer manage entire supply chain efficiently course also committed ensuring safety health new organizational structure working employee reducing company environmental collaboration shionogi family around world footprint advance company global drive build ensure safe reliable delivery osphenatm doribax ing production network enable u supply shionogi future global product patient around world group product worldwide putting place necessary foundation tangible intangible comply quality safety regulatory affair global gmp management division quality safety regulatory affair management divi cmc development laboratory sionhaving responsibility supplying pharmaceutical prod april cmc development laboratory became ucts reliable efficacy safety qualityhas central role independent organization within company enhance play enhancing reputation shionogi brand productivity across entire research development spec achieved complying shionogi product trum even greater cooperation pharmaceutical policy conforming strictly pharmaceutical affair research division pharmaceutical development division law regulation governing process rd intensive cmc research aimed improving devel launch gxp thereby ensuring patient around opment success rate broad range stage extending world use shionogi product peace mind drug research development market launch give full pharmaceutical product impact directly human life play cmc technology active pharmaceutical ingredi always pay meticulous attention risk management work ents api manufacturing formulation etc ability ing ensure strict quality control activity involving create viable product thus transform drug discovery seed shionogi productsnot manufacturing also raw mate global pharmaceutical product provide even higher rial procurement forth accordance strict level satisfaction patient law regulation europe u also comply fully inspection regulatory authority employing global scm division pharmaceutical quality management system build maintain shionogi identified first year improve capacity efficiently consistently supply company globalization line established topcaliber product global scm gscm division april gscm divi cmc refers chemistry manufacturing control sion purview cover group entire product range gxp general abbreviation good practice standardsnamely glp good charge controlling manufacture laboratory practice gmp good manufacturing practice gcp good clinical time much quantity quality practice gvp good pharmacovigilance practice supplying product market timely fashion shionogi annual report senior vice president message manufacturing division motto sqdce safety quality delivery cost environ ment based sqdce motto manufacturing division dedicated fostering fur ther advance production technology pursuing cost reform area considered offlimit ensure goal third mediumterm business plan met unwavering resolve upholding company policy intend strengthen cooperation division executive officer senior vice president manufacturing division takuo fukuda creation new drug demand overall competence research development cmc manufacturing role cmc development laboratory apply cmc technology chemistry manufacturing control compound deemed commercial poten tial reinvent pharmaceutical product suitable ingestion patient mission promote cmc souyaku cmcdirected innovative drug design devel opment approach enhance success rate new product launch combining pa sion younger researcher experience wisdom veteran form team professional pharmaceutical manufacturing corporate officer senior vice president cmc development laboratory kiyoshi nagata phd global scm division approach business three main goal strengthen company scm capability develop worldwide devise execute global production strategy cultivate human resource able accomplish order achieve goal set three policy establishment aggressive gscm system operational innovation ii firm cost control toward cash flow maximization iii maximization capacity event control individual change proceed business collaboration related division corporate officer senior vice president global scm division hirosato kondo phd quality safety regulatory affair management division set three main goal achieved third mediumterm business plan build imple ment global quality assurance system upgrade predictive preventive risk manage ment focus developing people achieve fiscal shionogi positioned first year group globalization extremely important u handle issue regarding postmarketing osphenatm properly maxi mization value act achievement goal make division much proactive active effective management development human resource corporate officer senior vice president quality safety regulatory affair management division takayuki yoshioka phd shionogi annual report management shionogis business shionogis csr activity management system financial section corporate information activity pipeline shionogi three priority therapeutic area infectious disease metabolic syndrome pain company also focusing frontier field allergy cancer area code generic name product name category administration indication infectious disease cephem antibiotic injection infection angiotensin receptor antagonist irbesartan trichlormethiazide combination diuretic combination oral hypertension metabolic cholesterol absorption inhibitor oral dyslipidemia syndrome insulin sensitizer oral type diabetes neuropeptide receptor antagonist oral obesity duloxetine hydrochloride cymbalta serotonin noradrenaline reuptake inhibitor oral fibromyalgia ly duloxetine hydrochloride cymbalta serotonin noradrenaline reuptake inhibitor oral chronic low back pain treatment moderate severe oxycodone hydrochloride hydrate oxycontin natural opium alkaloid oral chronic pain pain naldemedine peripheral opioid receptor antagonist oral alleviation opioidinduced adverse effect analgesic agent neuropathic pain oral neuropathic pain analgesic agent inflammatory pain oral inflammatory pain bladder cancer peptide cancer peptide vaccine injection esophageal cancer vaccine head neck squamous cell carcinoma peptide vaccine injection agerelated macular degeneration ospemifene selective estrogen receptor modulator oral postmenopausal vaginal atrophy eutectic mixture anesthetic metereddose topical psd lidocaine prilocaine aerosol spray premature ejaculation prostaglandin receptor antagonist oral allergic rhinitis sublingual tablet housedust mite allergen extract allergic rhinitis caused housedust frontier immunotherapy mite allergen guanfacine hydrochloride alphaaadrenergic receptor agonist oral attention deficit hyperactivity disorder lisdexamfetamine da ne reuptake inhibitor releaser da ne oral attention deficit hyperactivity disorder lusutrombopag small molecule tpo mimetic oral thrombocytopenia egfr dual inhibitor oral malignant tumor nfkb decoy oligodeoxynucleotide topical atopic dermatitis gsk dolutegravir integrase inhibitor oral hiv infection outlicensing gsk lap integrase inhibitor injection hiv infection activity nonpeptide mimetic trh oral spinocerebellar ataxia janssen shionogi bace inhibitor bace inhibitor oral alzheimers disease long acting parenteral formulation shionogi annual report august stage territory submission origin development phase phase iia phase iib phase iii approval japan shionogi glaxosmithkline inhouse uk u irbesartan sanofi france japan trichlormethiazide shionogi inhouse approval june shionogi kotobuki japan kotobuki pharmaceutical co ltd japan pharmaceutical co ltd u inhouse inhouse u japan eli lilly company u shionogi eli lilly japan kk japan japan napp pharmaceutical limited uk global inhouse inhouse japan preparation u pom proof mechanism shionogi purdue pharma shionogi purdue pharma lp u lp japan asia japan oncotherapy science inc japan inhouse europe japan u approval february shionogi quatrx pharma quatrx pharmaceutical company u ceuticals company europe nda submission march shionogi plethora solu u plethora solution holding plc uk tions holding plc japan u inhouse inhouse europe pom proof mechanism japan stallergenes sa france japan shire ireland shionogi shire japan japan preparation u europe inhouse inhouse europe japan anges mg inc japan shionogi anges mg inc global nda submission december shionogiviiv healthcare llc viiv healthcare ltd uk u kissei pharmaceutical co japan ltd japan inhouse janssen pharmaceutical europe inc u shionogi annual report management shionogis business shionogis csr activity management system financial section corporate information activity major product prescription drug strategic product shionogi work steadily expand share japanese market focusing strategic product crestor tablet irbetan tablet aimix combination tablet cymbalta capsule hyperlipidemia treatment irtra combination tablet irbetan family drug treatment depression depres launched april antihypertensive sive condition diabetic neuro irbetan tablet launched june aimix combination tablet launched pathic pain december irtra combination tablet preparation launch launched april shionogideveloped product statin therapy crestor longacting angiotensin ii receptor blocker arb strong hourlasting cymbalta serotonin noradrenaline proven highly effective lowering ldl hypotensive effect antimetabolic organprotecting effect following reuptake inhibitor approved antide cholesterol leader among dyslipid launch aimix combination tablet combining calcium pressant country emia treatment japan overseas antagonist amlodipine shionogi making preparation launch recommended firstline treatment reduces risk atherosclerotic irtra combination tablet combining diuretic trichlormethiazide diabetic neuropathic pain dnp disease affords physician patient domestic international guideline greater sense satisfaction reliance sale billion yen fiscal forecast crestor tablet fiscal irbetan family fiscal cymbalta capsule crestor royalty income fiscal overthecounter otc drug overthecounter otc drug business shionogi working improve people quality life qol offering range otc drug product tailored individual lifestyle popon series sedes line line multiple vitamin mineral providing nutri line analgesic antipyretic chosen according pain tive support healthy life following initial launch prescription drug analgesic antipyretic sedes made popon brand long established history providing debut otc drug shionogi offer lineup sedes product tailored comprehensive nutritional support people need recently customer pain usage need among product sedes hi containing isopropylan stepped extended popon lineup includes popons tipyrine acetaminophen sedes hi demonstrates strong analgesic effect acute pain longselling multiple vitamin mineral originally launched drug class based repeat use ratio product include sedes popon tablet marked st anniversary popons hi g granule sedes first recommended firsttime analgesic user plus updated upgraded version popons featuring iron include ingredient cause drowsiness gentle stomach folic acid calcium high need modernday people popons royal personalized people senior life source survey dentsu retail marketing inc based data collected major drugstore nation wide participating survey panel store stage intended provide survey target analgesic antipyretic purchaser august july people ageadjusted nutritive top brand purchase amount support healthy life shionogi annual report launch date japanese market oxycontin tablet oxinorm powder finibax intravenous drip infusion differin gel oxifast injection finibax solution kit intravenous topical acne vulgaris treatment oxycontin family drug drip infusion launched october cancer pain analgesic carbapenemtype antibiotic differin gel first topical retinoid oxycontin tablet launched july oxinorm powder launched september preparation japan indicated launched september oxifast injection launched shionogideveloped product acne vulgaris may finibax carbapenemtype antibiotic guideline cite differin gel highly combination shionogis hour sustainedrelease injection strong antibacterial activity recommended base acne vulgaris treat oxycontin tablet immediaterelease oxinorm powder pseudomonas aeruginosa ment treatment light severe enables cancer pain relieved effectively increasing expectation surround symptom following launch new oxifast injection ing product effectiveness treat patient difficulty taking oral drug ment serious intractable infection access treatment sepsis pneumonia peritonitis pirespa tablet rapiacta intravenous drip infusion idiopathic pulmonary fibrosis treatment antiviral drug influenza launched december launched january pirespa world first drug indicated rapiacta world first neuraminidase enzyme idiopathic pulmonary fibrosis inhibitor intravenous drip infusion pirespa expected inhibit decrease singledose intravenous drip infusion rapi vital capacity slow progression idio acta expected produce reliable treatment pathic pulmonary fibrosis benefit enabling used treat outpatient hospitalized patient age group infant elderly sale billion yen fiscal oxycontin family forecast fiscal finibax intravenous drip infusion finibax solution kit intravenous drip infusion fiscal differin gel pirespa tablet fiscal rapiacta intravenous drip infusion diagnostics diagnostic product business shionogi provides diagnostic reagent useful diagnosing assessing disease among purpose addition prescription drug business shionogi contributing wellbeing people diagnostic product business enabling early diagnosis treatment provision diagnostic reagent mi shionogi bnp launched december brightpoc flu shionospot bnp launched september quick influenza testing kit bnp kit launched september diagnostic product measure hormone bnp human brightpoc flu testing kit used quickly determine whether brain natriuretic peptide useful indicator diagnosing patient infected influenza virus kit provide assessing cardiac insufficiency therapeutic guideline cite testing positive test result within minute influenza type virus bnp blood level diagnostic reagent useful type b virus infection mean screening people sign cardiac insufficiency allerport tarc checkart quick testing system th chemokine tarc kit standard diabetes diagnosis marker launched february launched february allerport tarc support assessment severity atopic checkart testing system designed quickly measure dermatitis treatment benefit evaluation measuring hbac hemoglobin ac glucose level blood serum level tarc thymus activationregulated hbac glucose indicator used diagnose chemokine believed play key role patho manage diabetes genesis atopic dermatitis shionogi annual report management shionogis business activity shionogis csr management system financial section corporate information activity fundamental policy csr executive officer yoshiaki kamoya shionogi group set forth goal corporate activity strive constantly supply best possible medicine protect health wellbeing patient serve company policy instituted eternal unwavering corporate philosophy statement vision value society operation pharmaceutical company inherently contribute society believe implementing philosophy promotes fulfillment social respon sibilities corporation also formulated shionogi charter conduct guide effort conducting corpo rate activity suited truly rich vibrant civil society corporate citizen phar maceutical manufacturer awareness social responsibility based high ethical value recent year expected company term csr corporate social responsibility activity line trend shionogi actively implementing csr activity creating inno vative pharmaceutical developing specialized human resource fulfill corporate respon sibility economy environment society earn trust understanding society good corporate citizen shionogi charter conduct company contributes maintenance improvement health people around world well comfortable life shionogi formulated charter conduct hope activity benefit stakeholder including patient shareholder general public lead growth individual employee shionogi employee pledge act spirit charter conduct senior management take responsibility serving role model rigorously ensuring charter conduct understood time pledge establish refine effective internal system conforming company rule action corporate citizen action pharmaceutical company action shionogi compliance discovery original innovative pharma raison detre external relation ceuticals provision affordable trust society transaction distribution pharmaceutical individual organiza information management drug development proper procedure tional growth disclosure strict compliance pharmaceutical respect individual antisocial force related law regulation acceptance diversity environmental protection stable supply highquality pharmaceutical tradition social contribution activity promotion proper use manufacture transformation sale fulfilling satisfying workplace shionogi annual report community relation public awareness activity ministry health labour welfare mhlw identified five medium using mean help improve public awareness disease category afforded top priority healthcare plan disease view enhancing patient awareness namely mental illness diabetes malignant neoplasm cerebrovascular facilitating early discovery disease ischemic heart disease shionogi engaging mass main public awareness activity disease description public awareness activity mental illness program promoting return work people suffering depression refer diabetes use website leaflet distribution forth provide information diabetic neuropathic pain malignant neoplasm cancer pain educational activity refer cerebrovascular disease use website mean provide information importance cholesterol manage ischemic heart disease ment order prevent onset arteriosclerotic disease heart attack angina stroke idiopathic pulmonary fibrosis use animated website video message specialist physician forth provide information designated intractable illness acne program supported dedicated nikibi wa hifuka e visit dermatologist acne website encour aging acne patient seek appropriate advice dermatologist rather suffering alone influenza use event website mean provide information wearing mask hay fever health management five major disease category helping depression sufferer return work cancer pain awareness campaign according mhlw every year half million people stay study found japan patient suffering away work depression government figure put cancer pain receiving treatment pain nearly half combined economic cost suicide depression case receiving treatment made complaint concerning cancer pain billion suggested however reemployment depres health care professional see figure sion sufferer hampered dearth support scheme shionogi hold symposium health care professional cancer receptive workplace well factor patient family stress importance patient shionogi aim help find solution problem supporting informing health care professional pain symptom mean nikkei business publication inc depression rework working securing prompt treatment early relief cancer pain group group disseminates information various medium also operating dedicated website hosting symposium directed specialist physician counselor received pain relief never complained pain cancer pain management complained pain didnt receive pain relief mental health symposium nagoya source mmj june vol p shionogi annual report management shionogis business activity shionogis csr management system financial section corporate information activity community relation participation global health innovative socieour social contribution support association technology fund shionogi established socie company employee shionogi participating global health innovative technology employee labor union cooperate supporting socie member fund ghit fund contribute health people throughout voluntary social contribution activity socie provides assistance world especially developing world disaster japan specified japan disaster relief act ghit fund international nonprofit foundation dedicated well region overseas affected earthquake storm advancing development japan new medicine control volcanic eruption disease endemic developing country including three disaster also make annual devastating infectious disease hiv aid malaria tubercu donation various group losis neglected tropical disease ntds fiscal mark th anni participation ghit fund offer shionogi unique opportunity versary socie donated electronic strengthen healthcare developing country business piano item ronald focusing time development innovative medi mcdonald house charity japan cines improve life patient suffering infectious disease ronald mcdonald house charity japan including virus shionogi strives constantly accomplish mission established charity build ronald mcdonald house providing accommo provide innovative medicine patient developing nation dation sick child undergoing medical treatment family also aid indeed world ghit fund new important develops volunteer welfare medical care field element overall mission research grant two foundation shareholder investor communication hoansha foundation established march shionogi group discloses corporate data needed foundation established bequeath gisaburo earn appropriate share price proper timely manner shiono company second president conduct activity time promote twoway communication shareholder aim contributing advance pharmaceutical science providing investor use feedback management grant research contributes end fiscal top management hold semiannual annual financial result foundation provided grant project across japan briefing first thirdquarter conference call domestic special grant project kansai region also held presenta institutional investor analyst time also disclose tions announce result research company shionogi every quarter progress research development rd pharmaceutical research center sprc attended many vital pharmaceutical manufacturer furthermore senior manage inhouse external researcher ment convenes annual rd briefing way sharing infor foundation url httpwwwshionogicojpho mation regarding current status direction rd japanese whole also distribute audio recording financial result rd briefing website cell science research foundation additionally actively conduct managementled ir activity established march institutional overseas investor u uk asia opinion foundation established mark th anniversary question hear course investor relation activity shionogis founding activity aim contribute effort find japan overseas fed back relevant internal party used cause understand disease prevent treat condition management furthermore june advancing research cellular level life science field completely refreshed cor developing young researcher japan promoting international porate website one exchange fiscal foundation provided research grant mean distribute informa provided support young researcher study overseas tion revamp trying inviting sending researcher international forum thereby enhance accessibility rd meeting contributing advance cell science research standability information needed foundation url httpwwwshionogicojpzaidan stakeholder well range japanese information available corporate website shionogi annual report relationship employee list one five value shionogis action guideline respect individual mean maintaining maximum respect diverse individuality everyone involved shionogi human resource system employee childcare leave shorter human resource development working hour childcare flexible working hour people human resource system shionogi put place human resource system place great employee emphasis producing result behavior modification childcare leave aim developing strong individual growing organization shorter working hour childcare compete globally evaluation system feature grading according flexible working hour duty remuneration reflects wage rate promotes growth individual contributing achievement organi zational goal way promoting growth motivating individual employee tackle achieve challenging target fy fair equitable personnel evaluation order employee grow job believe crucial occupational health safety properly evaluate achievement result develop mental health strategy ment performance duty give occupational health safety appropriate job remuneration benefit view order realize company policy shionogi recognizes importance shionogi clarifying evaluation standard disclosing information employee health safety work research production fair equitable basis providing extensive educational program facility chemical used safety health committee evaluator way shionogi increasing transparency workplace lead effort ensure chemical properly handled objectivity evaluation methodology addition giving well stored managed furthermore order prevent occupational appropriate feedback evaluation result company working injury illness caused facility equipment shionogi bolstering increase satisfaction evaluation system internal checking system time conduct rigorous safety inspection regularly work raise employee safety awareness human resource development concerning employee health shionogi promoting system shionogis basic stance human resource development people facilitate management working hour thereby create source company competitiveness support career framework preventing incidence chronically excessive work building right employee join shionogi hour also cooperate health insurance association ensure leave human resource development shionogi composed employee take part regular annual health checkup encour organic mix element including onthejob training offsite age employee receive testing adultonset gynecological training personal development believe growth illness way implementing measure individual employee lead growth organization maintain improve employee health promoting worklife balance mental health measure shionogi belief realizing company policy epitome address mental health shionogi specialized physician working achieving worklife balance thus promoting connection fulltime industrial physician established counseling various situation people face life raising child system includes outside employee assistance program eap caring relative engaging personal development policy way company implementing comprehensive state fulfilling one responsibility enhancing one skill range measure line japanese ministry health labour character human one feel satisfied fulfilled welfare four care policy selfcare managerial care onsite find greater richness one life result industrial staff health care external resourcebased care since december began issuing shionogi fiscal also conducting stress check employee worklife guide inhouse guidebook intro raise awareness mental physical health management duce various system designed bid prevent mental disorder support various life situation one way program provides support employee mental health promoting worklife balance shionogi worklife guide shionogi annual report management shionogis business activity shionogis csr management system financial section corporate information activity effort preserve environment effort preserve environment ensure employee understands importance environ promoting business activity shionogi group aware mental activity educate handling task large company important social responsibility give appropriate environmental impact commence work program consideration global local environment lessen envi cover general environmental education waste management chemical ronmental impact business activity established substance handling subject also prepared shionogi group environmental protection plan target accordance emergency situation earthquake fire disaster shionogi group basic environmental policy conduct hazardous substance leak range environmental preservation activity give consideration specify response procedure global environmental protection resource protection harmony communication reporting natural environment system well regularly con president ceo duct emergency response drill corporate executive meeting review response procedure chief environmental supervisor shionogi group central disaster drill kanegasaki plant environmental committee chief environmental management supervisor energy efficiency committee recognition kanegasaki plant sprc new wing environmental management shionogis kanegasaki plant received award minister committee environment recognition contribution sustainable business site subsidiary society th national convention promotion environmental environmental rs held october ministry environment committee committee r promotion forum production volume rose due department department increase production facility installation new equipment plant still able greatly improve recycling rate maintain improving production environmental management system process well properly assessing separating different iso environmental audit type industrial waste shionogi acquired iso certification four business site building sprc sprc also widely large environmental impact namely three manufacturing divi acclaimed environmental friendliness design receiv sion kuise site settsu plant kanegasaki plant research ing many award include award excellence division shionogi pharmaceutical research center sprc osaka prefecture osaka sustainable architecture award subsidiary shionogi analysis center co ltd shionogi pharma well nikkeis kinki new chemical co ltd also obtained certification office promotion award due every year also receive audit external organization factor facility fiscal certification renewed following audit japan functionality consideration chemical quality assurance ltd furthermore environmental audit environment conducted manufacturing plant research laboratory domestic production subsidiary confirm status environmental management satisfactory environmentrelated law regula sprc osaka tions complied environmental risk prop erly managed forth international standard environmental management system target phase shionogi group environ mental protection plan fiscal result compliance law regulation education present striving reduce group entire environmental training impact implementing initiative phase shionogi japan wide range environmental regulation shionogi group environmental protection plan fiscal fiscal group identifies law regulation governing activity shar target result activity fiscal follows ing pertinent information business site well conducting education program creating manual ensure legal compliance shionogi annual report n fiscal result benchmark promote measure conserve manufacturing research division took various fiscal year actual fy energy counter global step upgrading highly efficient boiler fy actual warming power supply equipment improving air fy actual reduce co emission compared conditioning control time domestic target fiscal benchmark year fiscal production subsidiary switched fuel oil gas fiscal year reduce basic unit energy boiler upgraded step led annual average co emission ton reduction co emission compared promote introduction highly energy benchmark fiscal year basic unit energy basic unit energy v fy efficient equipment facility affected start operation three new wing basic unit energy calculated dividing energy kanegasaki plant alongside factor usage production volume total floor area etc continue effort improve energy efficiency n fiscal result fy actual strengthen conservation resource worked reduce waste formulation waste disposal measure fy actual process manufacturing department reduce amount waste generated compared fiscal benchmark promoted rsreduce reuse recycle fy actual year reduction fiscal including reusing solvent recycling fy target promote zero emission waste liquid fy target waste sent landfill final disposal divided waste generated ton landfill disposal rate total waste generated defined zero emission n fiscal result fy actual strengthen management set voluntary control level chemical chemical substance stricter regulatory level fy actual reduce atmospheric emission dichloro controlling emission fiscal atmospheric fy actual methane manufacture active pharma emission dichloromethane increased ceutical ingredient apis compared kanegasaki plant due defective facility however fy target fiscal benchmark year continue look way achieving control use atmospheric emission atmospheric emission dichloromethane ton emission reduction target chemical substance promote proper treatment manage ment polychlorinated biphenyls pcbs n fiscal result promote understanding conducted employee training part environmental activity aware biodiversity ness biodiversity accordance fundamental philosophy guideline properly preserve expand endangered conduct concerning biodiversity formulated japan pharmaceutical plant specie company botanical manufacturer association addition research division conducted research garden conformity law concerning conservation sustainable use conduct education biodiversity biological diversity regulation use living modified organism asiasarum dimidiatum related law regulation invasion alien specie act aburahi facility botanical garden endangered plant maintained managed variety endangered plant looking increasing number plant n fiscal result promote introduction order reduce co exhaust gas emission fy actual lowemission vehicle raising fuel efficiency making progress fy actual use hybrid electric vehicle car introducing hybrid vehicle mr fiscal lent mr except cold region fy actual hybrid vehicle accounted vehicle excluding cold region japan fy target percentage point fiscal reflecting large number newly introduced vehicle ev hb car lent mr ratio ev hb ev hb mean electric vehicle hybrid vehicle respectively thirdparty opinion expert institute environmental management accounting iema provide u opinion effort improve reliability transparency disclosure environmental activity also receive advice environ mental friendliness environmental management status future activity shionogi annual report management shionogis business activity shionogis csr activity management financial section corporate information system corporate governance shionogi group recognizes social mission continually discover develop provide useful safe medicine help improve health people medical treatment around world well quality life shionogi also recognizes continuously faithfully accomplishing mission increase corporate value accordingly belief strongly carrying sound transparent management practice corporate governance system established corporate governance system shionogi group adopted company board auditor board auditor five member including three outside corporate governance system board director five member member board auditor order ensure greater transpar including three outside director order enhance manage ency fairness member board auditor audit director ment transparency accountability stakeholder furthermore performance duty meeting board director cor company established nomination advisory committee porate executive meeting compensation advisory committee advisory body board moreover company introduced corporate officer system director committee chaired outside director ensuring allow management policy reflected operation without selected director vetted evaluated fair honest delay built flexible operational execution structure able perspective multiple angle including assessment aptitude rapidly respond change operating environment furthermore impact management quality work performance appropriate corporate executive meeting unit created conduct delibera ness compensation tions regarding operational execution issue composed director standing member board auditor corporate officer responsible operation corporate governance structure april amount remuneration director annual general meeting shareholder member board auditor fiscal appointment appointment appointment amount remuneration paid dismissal dismissal dismissal nominating million advisory report audit board person base stock board committee director category remunerated remuneration bonus option total auditor director compensation director member independent advisory board supervision outside director accounting auditor committee election among director auditor dismissal accounting member audit representative compliance board auditor director committee outside member corporate board internal executive auditor among internal audit meeting member control corporate officer board auditor department department group company total outside director outside member board auditor selection policy outside director outside member board auditor conflict interest company individ selected individual know role outside director outside ual outside director outside member board auditor member board auditor give frank opinion risk conflict interest general shareholder advice company management right time selected individual outstanding insight ability based selected individual personality professional background experience specialist expertise relating management insight quality sincerely valued properly demonstrate insight ability company management team also stakeholder shionogi annual report message outside director akio nomura since appointment outside director felt shionogi pharmaceutical manufacturer conduct corporate activity based high ethical value accordance company policy state shionogi strives constantly supply best possible medicine protect health wellbeing patient serve order company earn trust society continuously develop must actively disclose information ensuring transparency decisionmaking shionogis board director make open fair manage ment decision always mindful accountability draw experience corporate manager place importance neutrality independent direc tor work increase corporate value objective perspective also work ensure shionogi develops contributes broadly society teppei mogi economic globalization gather pace important japanese company comply various law regulation country around world antitrust law u foreign corrupt practice act fcpa course observe law regulation japan shionogis management must sufficiently aware overseas law regulation executing business company develops business globally using experience related international legal affair contribute outside director refinement operation global compliance risk management system time offer appropriate advice legal focus management decision katsuhiko machida manufacturing industry including pharmaceutical business precious industry resourcepoor country like japan role play extremely large one indeed however amid increasing uncertainty surrounding global economy escalating competition greater demand swift management decisionmaking weighs risk reward based management experience global manufacturing company objective outside perspective shareholder stakeholder determined contribute even objective transparent man agement shionogi maintaining overarching perspective stakeholder reason selection outside director outside member board auditor name reason selection attendance outside akio nomura mr nomura abundant experience broad discernment senior corporate executive attended board director meeting director company belief make management decision placing importance objectivity impartiality management contribute highly transparent management independent director teppei mogi mr mogi abundant experience professional knowledge attorney law attended board director meeting company belief use experience knowledge make management deci sion placing priority observance social norm law ordinance contribute highly transparent management independent director katsuhiko machida mr machida abundant experience broad discernment senior corporate executive attended board director meeting global manufacturing business company belief make management deci appointment june sion placing importance objectivity impartiality management contribute highly transparent management independent director outside takeharu nagata mr nagata abundant experience broad discernment senior corporate executive attended board director meeting member company belief properly carry audit duty providing advice regarding attended board auditor meeting legality propriety operation executed director board shinichi yokoyama mr yokoyama abundant experience broad discernment senior corporate executive attended board director meeting company belief properly carry audit duty providing advice attended board auditor meeting auditor regarding legality propriety operation executed director kenji fukuda mr fukuda abundant experience professional knowledge attorney law attended board director meeting company belief use experience knowledge properly carry audit duty attended board auditor meeting providing advice regarding legality propriety operation executed director koichi tsukihara mr tsukihara abundant experience broad discernment senior corporate executive appointed june company belief properly carry audit duty providing advice regarding legality propriety operation executed director shionogi annual report management shionogis business activity shionogis csr activity management financial section corporate information system corporate governance status audit execution member board auditor receive report detail internal audit accounting audit independent auditor necessary join member board auditor receive regular monthly report accounting audit conducted independent auditor status result internal audit internal control exchange opinion respond way department company internal auditing department exchange opinion respond way furthermore mem name certified public accountant cpa bers board auditor cooperate internal control independent auditor department conduct investigation carry work name independent quickly address issue internal control perspective name cpa auditor designated limited akihiko masuda liability partner ernst young hideki maekawa shinnihon llc engagement partner assistant audit work nine cpa seven people including people passed cpa examination system expert strengthening internal control system accordance basic policy building internal control system addition shionogi make sincere effort ensure reli system approved board director based company ability financial reporting time comply act shionogi established system ensuring appropriateness internal control report system financial instrument operation board director annually evaluates state exchange act shionogi strengthening internal control financial management internal control system past year based reporting shionogi group whole work improve evaluation revise basic policy augment internal control quality management control framework information disclosure accordance company disclosure policy shionogi appropriate fair manner stakeholder order enhance group continuously discloses corporate information timely management transparency company widely trusted society risk management shionogi recognizes intrinsic risk factor organizational situation shionogi formulated compendium pertaining specifi unit associated activity determines response strategy cally compendium disaster pandemic corporate scandal work avoid mitigate risk response policy well bcp guideline based crisis management policy accor important risk could significantly impact company manage dance shionogi promoting crisis management process ment discussed corporate executive meeting emphasize respect human life demonstrate consideration meeting necessary measure implemented regarding risk contribution local community mitigate potential damage associated disaster accident corporate scandal corporate value shionogi annual report thorough compliance shionogi work instill importance compliance shionogi bureau compliance committee draft compliance mea group employee request compliance performance accordance sure proposal group whole provides support shionogi group compliance policy order ensure compli promotion activity department unit well run compli ance law regulation ethical behavior business activi ance training program employee april company tie specifically led compliance committee chaired formulated disseminated shionogi code practice president company engages following type activity time distributed revised version shionogis compliance hand company designates compliance manager depart book employee providing reminder regarding compliance ment unit along compliance promoter assistant shionogi also work improve internal audit strengthen officer take step identify prevent compliance risk based monitoring verify effectiveness internal control system compliance risk management action plan department unit time working discover early prevent compliance time work increase effectiveness compli violation fully utilizing internal control system ance assurance integrated management across company progress reported compliance risk management action report compliance promotion structure april president ceo corporate executive meeting compliance committee report cooperation general administration subsidiary corporate scandal risk subsidiary management shionogis compliance handbook deliberation committee department risk analysis assessment measure proposal countermeasure formulation implementation support cooperation compliance manager manager division unit assistance compliance promoter least one appointed division unit shionogi annual report management shionogis business activity shionogis csr activity management financial section corporate information system member board june earning trust stakeholder shionogi aim corporate entity trusted stakeholder including shareholder patient family medical community directly addressing various issue transparency high ethical value director front row left motozo shiono isao teshirogi back row left teppei mogi akio nomura katsuhiko machida chairman board joined company managing director company representative executive director representative director general manager marketing planning department senior managing director company president company motozo shiono director company general manager agro vet industrial chem general manager corporate planning division general manager accounting department division chairman board incumbent president ceo joined company executive officer executive general manager senior executive officer isao teshirogi phd general manager corporate planning department pharmaceutical research development division president ceo incumbent general manager secretary office senior executive officer executive general director company manager pharmaceutical research development general manager corporate planning department division outside director representative director president osaka gas representative director chairman osaka gas outside director company incumbent akio nomura co ltd co ltd director west japan railway company outside director royal hotel ltd incumbent outside director registration attorney law professor kwansei gakuin university law school outside director company incumbent teppei mogi partner ohebashi law office incumbent parttime instructor kobe university graduate parttime instructor kwansei gakuin partner ohebashi lpc partner incumbent school law incumbent university law school incumbent outside director president sharp corporation chairman chief executive officer sharp corporate advisor sharp corporation katsuhiko machida chairman sharp corporation corporation outside director company incumbent outside director sekisui house ltd incumbent chairman sharp corporation special advisor sharp corporation incumbent director corporate advisor sharp corporation shionogi annual report member board auditor left shinichi yokoyama sachio tokaji mitsuaki ohtani koichi tsukihara kenji fukuda standing member joined company general manager pharmaceutical development division executive general manager pharmaceutical board auditor director company general manager strategic development department research development division general mitsuaki ohtani general manager clinical research executive general manager pharmaceutical research manager discovery research laboratory department general manager product development division general manager discovery standing member board auditor phd research laboratory general manager strategic company incumbent development department development department standing member joined company corporate officer general manager accounting executive officer corporate business manage board auditor general manager accounting department financial department general manager international ment executive sachio tokaji director company business department director company senior executive general manager accounting financial corporate officer corporate business management officer department executive general manager accounting financial standing member board auditor department company incumbent corporate officer general manager accounting financial department outside member president sumitomo life insurance chairman representative director sumitomo life outside corporate auditor sumitomo chemical board auditor company insurance company incumbent co ltd incumbent shinichi yokoyama outside corporate auditor nec corporation outside member board auditor company incumbent outside member registration attorney law vice president osaka bar association outside member board auditor board auditor joined dojima law office governor japan federation bar association company incumbent kenji fukuda partner dojima law office incumbent visiting professor osaka university law school outside member deputy president executive officer representative director president director chairman sumitomo mitsui card board auditor sumitomo mitsui banking corporation sumitomo mitsui card co ltd co ltd incumbent koichi tsukihara vice president executive managing representative director chairman sumitomo mitsui outside director gurunavi inc incumbent officer sumitomo mitsui financial group card co ltd outside member board auditor company incumbent senior executive officer executive officer executive officer executive officer corporate officer takuko sawada takuo fukuda ryuichi kume yoshiaki kamoya hirosato kondo corporate phd phd officer corporate officer corporate officer corporate officer corporate officer corporate officer corporate officer corporate officer corporate officer kohji hanasaki takayuki yoshioka kiyoshi nagata masaaki goshima akio tsubokura masaaki takeyasu john keller phd shinya matsuzawa phd phd phd shionogi annual report management shionogis business activity shionogis csr activity management system financial corporate information section tenyear consolidated financial highlight shionogi co ltd consolidated subsidiary million yen year ended march net sale cost sale selling general administrative expense operating income income income tax minority interest net income research development expense capital investment depreciation amortization march property plant equipment net total asset total longterm liability total net asset per share amount net income net asset dividend equity ratio return equity roe payout ratio note u dollar figure calculated convenience rate us approximate rate exchange march scal year ended march company adopted new accounting standard presentation net asset balance sheet reclassies former shareholder equity valuation translation adjustment minority interest total net asset figure scal year year ended march calculated conformity new standard shionogi annual report thousand million yen u dollar yen u dollar shionogi annual report management shionogis business activity shionogis csr activity management system financial corporate information section management discussion analysis overview result sale prescription drug japan fiscal year ended march increased slightly year year despite effect nhi drug price revision shionogi group addition previously volatile result u operation stabilized shionogi group benefited groupwide cost reduc tions result factor shionogi group achieved record operating income net sale result gross profit increased year year net sale increased year year million million domestic sale prescription drug sale eight strategic product centered three core operating expense operating income strategic product hyperlipidemia treatment crestor selling general administrative sga expense increased hypertension treatment irbetan antidepressant drug however operating income increased year year cymbalta increased million compen million due factor including higher net sale sated lower sale existing product due nhi drug price improved gross margin ongoing cost reduction improved revision factor led overall increase earnings shionogi inc domestic sale prescription drug export overseas subsidiary income expense export overseas subsidiary sale increased substantially sale fiscal shionogi recorded net expense increased substantially year year u subsidiary shionogi million compared net expense million inc achieved stable operation throughout fiscal year fiscal addition chinabased pharmaceutical company co result viiv agreement covering hiv drug pharmaceutical technology holding limited co also con shionogi group recognized income million tributed full year sale gain exchange investment security difference royalty income carrying value shionogi group equity position crestor royalty income decreased astrazenecas global shionogiviiv healthcare lp market value fair value sale crestor decreased however total royalty income equity position viiv addition revising agree increased year year million due onetime ment shionogi considered reallocation management licensing fee alzheimers disease treatment resource u operation tested impairment goodwill sale right associated product shionogi inc han gross profit dle result shionogi recognized impairment loss fixed cost sale increased yearonyear term asset million million cost sale ratio decreased due increase sale u operation cost sale income income tax minority interest ratio low net income income income tax minority interest increased million including income tax adjustment net sale operating income billion yen billion yen fy fy shionogi annual report income tax negative million decrease improving success rate moving nonclinical clinical year year reflected large decline income tax due trial october shionogi group licensed treatment loss valuation stock affiliate booked alzheimers disease novel mechanism action nonconsolidated basis result aforementioned impair johnson johnson group company excellent experience ment shionogi inc expertise field alzheimers disease moreover net income increased million net shionogi group energetically collaborates university income ratio compared previous research institution japan around world sustain fiscal year net income per share increased discovery innovative new drug development activity present shionogi group developing strong pipeline segment information includes latestage development drug alleviating shionogi group operates single business segment related opioidinduced adverse effect allergic rhinitis prescription drug involving research development pur treatment february shionogi group chasing manufacturing distribution related business established wholly owned subsidiary shionogi limited prescription drug shionogi performs analysis sale london united kingdom development base europe product evaluation performance group company shionogi group move forward faster effec decision business strategy allocation management tive triregional development united state europe resource especially allocation research development asia enable rapid supply drug global market expense made groupwide basis therefore disclosure inlicensing product technology segment information year ended march october shionogi group kotobuki omitted pharmaceutical co ltd nagano prefecture concluded license agreement covering worldwide right develop manufac research development expense ture commercialize cholesterol absorption inhibitor koto shionogi group aim achieve worldclass research produc buki code name kt owned kotobuki product tivity quickly supply pharmaceutical global market expected lower serum cholesterol level selectively inhibit conducting research development rd activity group ing cholesterol transporter small intestine shionogi quickly identifies unmet medical need medical need group committing providing new option treating meta addressed reason including lack effective treatment bolic syndrome one targeted therapeutic area enhances strength small molecule drug discovery result activity overall group rd expense deploys various leadingedge technology develop large mol fiscal totaled million ecule drug continuously supply innovative pharmaceutical patient worldwide cash flow research activity fiscal net cash provided operating activity increased july shionogi group completed shionogi phar million compared previous fiscal year maceutical research center sprc aim consolidating million income income tax minority interest strengthening research function sprc energetically con increased depreciation amortization noncash ducting activity aim strengthening organiza item decreased tional cooperation increasing candidate development net income rd expense billion yen billion yen fy fy shionogi annual report management shionogis business activity shionogis csr activity management system financial corporate information section management discussion analysis net cash used investing activity decreased million total liability amounted million decrease compared previous fiscal year million million primarily reflected loss carry forward absence use cash connection co acquisition discussed reduced accrued income tax fiscal main u cash purchase property group redemption bond repayment longterm debt plant equipment connection construction net asset totaled million million year betalactam injectable drug facility new production facility year total shareholder equity increased million highpotency active pharmaceutical ingredient million mainly net increase retained net cash used financing activity increased million earnings addition net income deduction compared previous fiscal year million dividend accumulated comprehensive loss net decreased result factor included redemption bond payable million million year earlier due repayment debt payment dividend impact exchange rate stock price share subscription right result cash cash equivalent march increased million minority interest increased million increased million million reflecting various factor ratio total net asset total asset increased capital investment capital investment shionogi group fiscal totaled dividend million million year year shionogi aim raise dividend steadily line performance company invested million mainly manufactur proactively making business investment increase corpo ing facility expansion including construction betalactam rate value medium longterm perspective shionogi injectable drug facility new production facility high group making steady progress growth initiative potency active pharmaceutical ingredient furthermore total therefore raised target consolidated dividend payout million invested consolidated subsidiary shionogi inc ratio return profit shareholder elsewhere shionogis article incorporation stipulate twiceyearly distri butions retained earnings interim final dividend wher asset liability net asset ever possible general meeting shareholder must approve march total asset stood million final dividend board director approves million march current asset interim dividend increased million year year million consolidated net income fiscal includes reduced tax increase due mainly loss carry forward company payment connection loss valuation stock resulted increase deferred income tax income affiliate excluding onetime tax effect based tax receivable noncurrent asset increased million policy shionogi decided increase yearend cash dividend year earlier million mainly increase fiscal per share forecast beginning investment security resulting acquisition viiv fiscal year together interim cash dividend total share outweighed decrease goodwill marketing right due annual dividend per share consolidated dividend impairment payout ratio total asset billion yen fy shionogi annual report business risk main type risk might significant impact risk dependence certain product shionogi group management performance financial condi shionogi group obtains approximately product sale tion listed royalty income two product crestor flomox forwardlooking statement text reflect group fiscal incidence unexpected factor judgment march cause drop discontinuation sale one product possibility might impact systemic regulatory risk group performance pharmaceutical industry revision national health insurance nhi system considered including revision intensification global competition nhi drug price system trend could affect result global competition involving nonjapanese company phar shionogi group addition increase strictness maceutical industry rd sale operation becoming increas japanese overseas regulation concerning item ingly intense development manufacture pharmaceutical could present group additional expense make difficult prod risk alliance company ucts comply regulation possibility shionogi group engages diverse form alliance might impact group performance company respect joint research joint development joint marketing activity including cooperation risk adverse drug reaction form cooperative research project cooperative development pharmaceutical entail risk unanticipated adverse drug reac project inlicensing outlicensing technology tions could involve termination sale product recall cooperative marketing project situation change outcome could affect result shionogi group eliminate cooperative relationship might impact group performance pharmaceutical rd risk pharmaceutical rd requires substantial commitment resource risk natural disaster pandemic time addition new drug subject numerous uncer sudden occurrence natural disaster unforeseen tainties prior start actual sale incident pandemic could dictate closure plant labora tory business site shutdown plant intellectual property risk could affect result shionogi group shionogi group u patent intellectual property protect pharmaceutical discovers generate income capital market foreign exchange risk however various type intellectual property may unable fluctuation stock foreign exchange market exceed provide adequate protection may infringe intellectual projected range could affect result financial position property third party shionogi group furthermore expiry intellectual property right pat ents pharmaceutical developed shionogi launch risk sale generic expiry could affect result addition abovelisted risk shionogi group business shionogi group activity involve risk lawsuit risk related regulatory political economic factor diverse risk list risk include type risk shionogi group exposed main patent litigation shionogi group interested party july country product technology plaintiff defendant court filing date current status high court shionogi patent holder generic product sale established june u crestor december astrazeneca company apotex inc etc settled cobalt pharmaceutical inc march watson pharmaceutical inc shionogi patent holder u crestor actavis inc october settled march astrazeneca egis pharmaceutical fortamet shionogi lupin ltd settled mylan inc march u january shionogi inc product andrx corp patent holder mylan inc settled lupin ltd may shionogi patent holder doribax u peninsula pharmaceutical inc sandoz inc december decision pending japan product name finibax janssen pharmaceutical inc doribax sandoz inc u shionogi patent holder december decision pending japan product name finibax hospira inc shionogi annual report management shionogis business activity shionogis csr activity management system financial corporate information section consolidated financial statement consolidated balance sheet shionogi co ltd consolidated subsidiary march thousand u dollar million yen note asset current asset cash cash equivalent note shortterm investment note note account receivable note affiliate trade allowance doubtful account inventory note deferred income tax note current asset total current asset property plant equipment land note building structure note machinery equipment vehicle furniture fixture construction progress accumulated depreciation property plant equipment net investment asset investment security note investment affiliate note prepaid pension cost note goodwill note marketing right note longterm prepaid expense deferred income tax note asset total investment asset total asset shionogi annual report thousand u dollar million yen note liability net asset current liability note account payable note affiliate trade construction shortterm bank loan note current portion longterm debt note allowance employee bonus provision sale return accrued expense accrued income tax note deferred income tax note current liability note total current liability longterm liability longterm debt note accrued retirement benefit employee note deferred income tax note longterm account payableother longterm liability total longterm liability contingent liability note net asset shareholder equity note common stock authorized share issued share capital surplus retained earnings less treasury stock cost total shareholder equity accumulated comprehensive income loss net unrealized holding gain security deferred loss hedge note translation adjustment accumulated comprehensive loss net share subscription right minority interest total net asset note total liability net asset see accompanying note consolidated financial statement shionogi annual report management shionogis business activity shionogis csr activity management system financial corporate information section consolidated financial statement consolidated statement income shionogi co ltd consolidated subsidiary year ended march thousand u dollar million yen note net sale note cost sale note gross profit selling general administrative expense note operating income income expense interest dividend income interest expense loss disposal property plant equipment gain sale land gain exchange investment security gain sale investment security note loss sale fixed asset note impairment loss fixed asset note loss disaster note litigation settlement note contract termination cost loss devaluation investment security note special retirement benefit expense note business structure improvement expense note net income income tax minority interest income tax note current deferred income minority interest minority interest net income note see accompanying note consolidated financial statement shionogi annual report consolidated statement comprehensive income shionogi co ltd consolidated subsidiary year ended march thousand u dollar million yen note income minority interest comprehensive income note net unrealized holding gain security deferred loss gain hedge translation adjustment comprehensive income net comprehensive income comprehensive income attributable shareholder shionogi co ltd minority interest see accompanying note consolidated financial statement consolidated statement change net asset shionogi co ltd consolidated subsidiary year ended march million yen total total net unrealized accumulated share common capital retained treasury shareholder holding gain deferred loss translation compre subscription minority total stock surplus earnings stock cost equity security hedge adjustment hensive loss right interest net asset balance april net income dividend purchase treasury stock change balance april net income dividend disposal treasury stock purchase treasury stock change balance march thousand dollar note total total net unrealized accumulated share common capital retained treasury shareholder holding gain deferred loss translation compre subscription minority total stock surplus earnings stock cost equity security hedge adjustment hensive loss right interest net asset balance april net income dividend disposal treasury stock purchase treasury stock change balance march see accompanying note consolidated financial statement shionogi annual report management shionogis business activity shionogis csr activity management system financial corporate information section consolidated financial statement consolidated statement cash flow shionogi co ltd consolidated subsidiary year ended march thousand u dollar million yen note operating activity income income tax minority interest adjustment depreciation amortization impairment loss fixed asset amortization goodwill net loss gain sale disposal property plant equipment gain sale investment security loss devaluation investment security gain exchange investment security decrease provision loss disaster decrease increase accrued retirement benefit employee interest dividend income interest expense change operating asset liability note account receivable inventory current asset note account payable accrued expense current liability subtotal interest dividend received interest paid income tax paid net cash provided operating activity shionogi annual report thousand u dollar million yen note investing activity increase shortterm investment proceeds sale redemption shortterm investment increase investment security proceeds sale redemption investment security purchase property plant equipment purchase intangible asset increase investment affiliate acquisition investment subsidiary resulting change scope consolidation net cash used investing activity financing activity increase shortterm bank loan net proceeds longterm debt repayment redemption longterm debt purchase treasury stock cash dividend paid net cash used financing activity effect exchange rate change cash cash equivalent net increase decrease cash cash equivalent cash cash equivalent beginning year cash cash equivalent end year see accompanying note consolidated financial statement shionogi annual report management shionogis business activity shionogis csr activity management system financial corporate information section consolidated financial statement note consolidated financial statement basis preparation amounted million thousand million accompanying consolidated financial statement shionogi co thousand million thousand million ltd company consolidated subsidiary collectively thousand respectively group prepared basis accounting principle generally addition co subsidiary total company accepted japan different certain respect changed fiscal yearend date june december application disclosure requirement international financial ever change effect consolidated financial result reporting standard compiled consolidated financial statement prepared company required financial b foreign currency translation instrument exchange act japan monetary asset liability denominated foreign currency preparing accompanying consolidated financial statement translated yen rate exchange effect balance certain reclassification made consolidated financial sheet date gain loss translation credited statement issued domestically order present format charged income familiar reader outside japan revenue expense item arising transaction denominated addition note consolidated financial statement foreign currency generally translated japanese yen rate include certain information required accounting exchange effect respective transaction date gain loss principle generally accepted japan presented herein addi foreign exchange credited charged income period tional information gain loss recognized financial reporting purpose certain reclassification previously reported amount asset liability overseas consolidated subsidiary made conform consolidated financial statement year translated yen rate exchange effect balance ended march presentation reclassification sheet date revenue expense overseas consolidated sub effect consolidated net income net asset sidiaries translated yen average exchange rate component net asset excluding minority interest translated summary significant accounting policy historical exchange rate adjustment resulting translating principle consolidation accounting investment foreign currency financial statement included deter affiliate mination net income reported translation adjustment accompanying consolidated financial statement include accumulated comprehensible income loss consolidated account company company controlled directly balance sheet indirectly company company company exer ci significant influence term operating financial c cash cash equivalent policy included consolidated financial statement cash cash equivalent include cash hand bank equity basis company applied equity method highly liquid investment maturity three month less investment three affiliate year ended march purchased investment affiliate accounted equity method carried cost shortterm investment investment security significant intercompany account transaction security classified three category trading security heldto eliminated consolidation maturity debt security security trading security consisting fiscal year end seventeen overseas consolidated subsidiary debt marketable equity security stated fair value gain december different company sub loss realized unrealized charged income heldto sidiaries consolidated using financial statement maturity debt security stated amortized cost marketable securi year ended december fiscal year end one overseas con tie classified security carried fair value solidated subsidiary june year ended march change unrealized holding gain loss net applicable income consolidation purpose financial statement subsidiary tax reported separate component net asset nonmarketable prepared sixmonth period ended december security classified security carried cost determined result adjustment made significant transaction moving average method investment investment partnership taking place period january march stated amount net asset attributable ownership fiscal year ended march fiscal yearend date percentage company taiwan shionogi co ltd changed december march result change financial statement taiwan e derivative shionogi co ltd fiscal year ended march cover derivative carried fair value month january march consoli dated financial result fiscal year ended march f inventory period january march net sale inventory principally stated lower cost determined operating income ordinary income income income tax average method net selling value taiwan shionogi co ltd eliminating intercompany transaction shionogi annual report g property plant equipment leased asset n retirement benefit property plant equipment stated cost company defined benefit pension plan known cash depreciation property plant equipment calculated balance plan allows pension benefit fluctuate accordance straightline method estimated useful life respective market interest rate also lumpsum payment plan asset defined contribution pension plan certain domestic consolidated useful life property plant equipment summarized subsidiary lumpsum payment plan defined contribution follows pension plan addition certain consolidated subsidiary defined contribution pension plan certain case group may building structure year also pay special retirement benefit subject actuarial machinery equipment vehicle year calculation accrued retirement benefit provided based amount significant renewal addition capitalized cost mainte projected benefit obligation reduced pension plan asset nance repair charged income incurred fair value year end prior service cost amortized straightline method h lease period year within estimated average remaining finance lease transaction transfer ownership depreci year service eligible employee ated nil residual value period lease contract using actuarial gain loss amortized year following year straightline method gain loss recognized principally straightline finance lease transaction entered march method period year within estimated aver transfer ownership continue accounted age remaining year service eligible employee operating lease provision sale return goodwill company provides reserve sale return amount goodwill amortized year straightline method estimated loss expected incurred subsequent balance sheet date based product sale margin historical sale return ratio j research development expense computer certain consolidated subsidiary provide reserve sale return software amount estimated loss expected incurred subsequent research development expense charged income balance sheet date based total product sale historical sale incurred expenditure relating computer software developed return ratio internal use charged income incurred unless deemed contribute generation future income cost saving p hedge accounting expenditure capitalized asset amortized straightline company utilizes derivative transaction mitigating fluctua method respective estimated useful life generally period tion risk foreign currency asset liability forecast transaction year interest rate loan hedging instrument forward foreign currency exchange contract currency option interest rate swap k income tax agreement hedged item foreign currency asset liability fore income tax calculated based taxable income charged cast transaction interest rate loan financial institution income accrual basis certain temporary difference exist gain loss derivative position designated hedge deferred taxable income income reported financial statement loss gain respective underlying hedged item purpose enter determination taxable income recognized interestrate swap meet certain condition different period accounted interest rate applied swap originally applied underlying debt special accounting treatment l allowance doubtful account forward foreign exchange contract meet certain criterion company consolidated subsidiary provide allowance accounted allocation method requires recognized doubtful account amount calculated based historical foreign currency receivables payable translated corre experience bad debt ordinary receivables plus additional sponding contract rate estimate probable specific bad debt customer experiencing company evaluates effectiveness hedging activity financial difficulty compared movement cash flow hedging instrument corresponding movement cash flow hedged item allowance employee bonus however regard forward foreign exchange contract allowance employee bonus provided estimated amount accounted allocation method interestrate swap bonus paid employee following year accounted special accounting treatment evaluation effectiveness omitted shionogi annual report management shionogis business activity shionogis csr activity management system financial corporate information section consolidated financial statement q distribution retained earnings effect change increase gross profit million corporation law japan distribution retained earn thousand operating income million ings respect given financial period made resolution thousand ordinary income income income tax shareholder general meeting held subsequent close minority interest million thousand respectively financial period account period reflect year ended march corresponding amount distribution refer note would recorded previous method change accounting policy accounting standard issued yet change depreciation method effective shionogi group changed method depreciation prop may accounting standard board japan asbj erty plant equipment straightline method effective year issued accounting standard retirement benefit asbj statement ended march declining balance method mainly guidance accounting standard retirement ben applied past efits asbj guidance replace accounting standard third mediumterm business plan fiscal retirement benefit issued business account shionogi group implementing fundamental strategy achieve ing council effective date april steady growth transitioning former organization mainly related practical guidance followed partial amendment corresponding product experienced rapid growth soon time time launch new one focusing eight strategic product standard require entity recognize overfunded expected achieve stable longterm earnings addition underfunded status defined benefit pension plan asset shionogi group pursuing fundamental strategy establish greater liability consolidated balance sheet actuarial gain loss presence north america europe asia aiming globalization prior service cost recognized part pension expense new drug development recognized part comprehensive income purpose expanding sale eight strategic product amount recognized accumulated comprehensive mentioned shionogi group completed consolidating income prior period recognized consolidated state strengthening manufacturing facility constructing ment income current period component pension benefit plant solid preparation well strengthening tablet granu expense treated reclassification adjustment lation facility addition shionogi group expects sale retirement benefit obligation attributed period eight strategic drug first time accounted benefit formula basis straightline method calcu net sale year ended march account lation method discount rate shall changed higher percentage future addition consolidated subsidiary accounting standard related guidance effective established united kingdom shionogi ltd began operation end fiscal year beginning april however year ended march resulted comple amendment calculation method retirement benefit obliga tion establishing sale structure shionogi group north tion service cost applied effective april america europe asia result shionogi group reviewed company currently evaluating effect modifica method depreciation property plant equipment changed tions consolidated result operation financial straightline method following reason reflect sub position stance shionogi group operation appropriately u dollar amount shionogi group formerly focused product experi translation yen amount u dollar amount included enced rapid growth soon launch enabled comparatively solely convenience matter arithmetic computation faster cost recovery facility investment transition us approximate rate exchange effect focus eight strategic product expected generate march translation construed repre longterm earnings facility utilization also expected sentation yen could could future consistent stable converted u dollar rate overseas subsidiary principally applied straightline shortterm investment investment method property plant equipment shionogi group security therefore required unify accounting policy appli information heldtomaturity debt security march cation straightline method effectively efficiently allo omitted due immateriality cate resource among unified network base japan north america europe asia contribute construction maintenance operation global research development production sale organization shionogi annual report marketable security classified security march inventory follows inventory march follows million yen thousand million yen u dollar gross gross acquisition unrealized unrealized carrying merchandise cost gain loss value finished good equity security semifinished good government bond work process municipal bond etc raw material supply security million yen shortterm bank loan longterm debt annual average interest rate applicable shortterm bank loan gross gross march acquisition unrealized unrealized carrying cost gain loss value longterm debt march consisted equity security following thousand government bond million yen u dollar municipal bond etc security unsecured loan bank financial institution due average interest rate thousand u dollar unsecured bond due gross gross acquisition unrealized unrealized carrying average interest rate cost gain loss value equity security unsecured bond due average interest rate government bond municipal bond etc security less current portion proceeds sale gross realized gain loss security year ended march sum unsecured loan included loan without interest amount marized follows million thousand thousand million yen u dollar aggregate annual maturity longterm debt subsequent march summarized follows proceeds sale thousand gross realized gain year ending march million yen u dollar gross realized loss loss devaluation investment security thereafter loss devaluation investment security recorded securi tie whose fair value declined decline deemed irrecoverable considering financial position security issuer factor pledged asset company recognized loss devaluation investment asset pledged collateral march follows security million thousand million thousand million yen u dollar year ended march respectively cash cash equivalent shionogi annual report management shionogis business activity shionogis csr activity management system financial corporate information section consolidated financial statement corresponding liability secured collateral march movement number stock option vesting follows plan plan company year thousand ended march summarized follows million yen u dollar plan plan number option number option deposit received employee outstanding april included current liability vested exercised contingent liability forfeited company contingently liable guarantee employee outstanding march housing loan million thousand march shareholder equity unit price stock option plan corporation law japan law provides amount company year ended march summarized equal amount disbursed distribution capital follow plan plan surplus capital reserve retained earnings yen u dollar yen u dollar legal reserve transferred capital reserve legal unit price stock option reserve respectively sum capital reserve legal exercise price march reserve equal capital stock account distribution made time resolution shareholder board average market price per director certain condition met share upon exercise company legal reserve included retained earnings march estimated fair value amounted million thousand unit price grant date law upon issuance sale new share common stock entire amount proceeds required valuation method estimating fair value blacksholes accounted common stock although company may resolu model major assumption used follows tion board director account amount exceeding major assumption note plan onehalf proceeds sale new share additional paidin estimated volatility capital included capital surplus estimated remaining period b year accordance law stock option plan two director estimated dividend c per share eleven corporate officer company approved annual riskfree rate general meeting shareholder company held june plan term plan share estimated volatility computed actual stock price common stock granted vested immediately option company period december july became exercisable july scheduled expire b estimated remaining period average period stock option july stock option expense million thousand holder retirement accordance internal regulation included selling general administrative expense c estimated dividend calculated actual amount year ended march year ended march way stock option plan three director nine riskfree rate based average rate compound corporate officer company approved annual general interest yield bond redemption date within three meeting shareholder company held june month estimated remaining period statistic data plan term plan share longterm interestbearing government bond published common stock granted vested immediately option japan security dealer association became exercisable july scheduled expire july stock option expense million included difficult reasonably estimate number stock selling general administrative expense year ended march option forfeited estimation reflects actual number forfeited stock option shionogi annual report movement issued share common stock treasury stock c risk management financial instrument year ended march summarized monitoring credit risk risk customer counterparties follows may default number share accordance procedure determined company accounting finance department related section com april increase decrease march pany periodically monitor condition major customer manage issued share collection due date balance customer try identify common stock credit risk customer worsening financial condition treasury stock early stage mitigate risk consolidated subsidiary perform similar credit management accordance internal rule number share company april increase decrease march company enters derivative transaction financial insti issued share tutions high credit rating mitigate counterparty risk common stock maximum amount credit risk balance sheet date repre treasury stock sented carrying value financial asset exposed credit risk company purchased share share common ii monitoring market risk risk arising fluctuation stock shareholder fractional share less one unit foreign exchange rate interest rate others year ended march respectively company utilizes forward foreign currency exchange contract company disposed share common stock exer currency option contract hedging mitigate fluctuation risk identi cise subscription right share year ended march fied foreign currency trade receivables payable fore casted transaction company also utilizes interest rate swap agreement control fluctuation risk interest rate loan financial instrument company continuously review security holding monitoring overview periodically market financial condition security issuer policy financial instrument company business relationship group also company obtains necessary funding principally bank borrowing review holding condition security heldtomaturities bond issuance business plan main business evaluating relationship company production sale pharmaceutical temporary surplus fund accounting finance department enters derivative trans managed lowrisk financial asset derivative utilized mitigat action rule determined company utilizes ing risk described later part note utilized ward foreign exchange contract currency option contract speculative purpose interestrate swap agreement within normal range transaction accounting finance department manages information b type financial instrument related risk transaction reporting periodically board director meet trade receivables note account receivable exposed ings consolidated subsidiary utilize derivative transaction credit risk customer trade receivables denominated foreign currency exposed fluctuation risk foreign currency iii monitoring liquidity risk risk group may able shortterm investment investment security exposed meet obligation scheduled due date fluctuation risk market price company manages liquidity risk accounting finance trade payable note account payable due within almost department preparing updating cash flow plan timely basis one year certain trade payable denominated foreign currency keeping necessary fund based report prepared import raw material exposed fluctuation risk department eign currency loan bond utilized principally necessary financing business plan maturity date due supplementary explanation estimated fair value six year longest subsequent march financial instrument derivative transaction made hedging foreign currency fluc fair value financial instrument based quoted market tuation risk trade receivables trade payable forecasted transac price available quoted market price available fair tions denominated foreign currency using forward foreign value reasonably estimated since various assumption factor exchange contract currency option contract hedging reflected estimating fair value different assumption factor interest rate fluctuation risk loan using interest rate swap agree could result different fair value addition notional amount ments refer hedge accounting note summary significant derivative note necessarily indicate market risk accounting policy information hedge accounting derivative transaction hedging instrument hedged item hedging policy forth shionogi annual report management shionogis business activity shionogis csr activity management system financial corporate information section consolidated financial statement million yen e concentration credit risk march percent percent respectively carrying value fair value difference outstanding trade receivables represented receivables due cash cash equivalent specific largescale customer note account receivabletrade affiliate fair value financial instrument shortterm investment carrying value financial instrument consolidated balance investment security sheet march fair value differ affiliate ences shown following table following table total asset include financial instrument extremely difficult deter note account payable mine fair value affiliate million yen trade current portion longterm debt carrying value fair value difference current portion longterm loan cash cash equivalent current portion longterm bond note account accrued income tax receivabletrade affiliate longterm debt shortterm investment investment security bond payable affiliate longterm loan total asset total liability note account payable derivative transaction affiliate trade thousand u dollar shortterm bank loan current portion longterm debt carrying value fair value difference current portion longterm loan cash cash equivalent accrued income tax note account receivabletrade affiliate longterm debt shortterm investment bond payable investment security longterm loan affiliate total liability total asset derivative transaction note account payable affiliate trade shortterm bank loan current portion longterm debt current portion longterm loan accrued income tax longterm debt bond payable longterm loan total liability derivative transaction asset liability arising derivative transaction shown net value amount parenthesis representing net liability position method determine fair value financial instrument short term investment investment security derivative transaction shionogi annual report asset c redemption schedule monetary asset marketable securi cash cash equivalent tie maturity march since item settled short time period carrying million yen value approximates fair value note account receivabletrade affiliate due due year year fair value account receivable require longer period due due collection determined based present value group year less year year year receivables classified collection term computed discount rate cash cash equivalent consideration credit risk corresponding collection term note account receivabletrade since account receivable settled short time period affiliate carrying value approximates fair value shortterm investment shortterm investment investment security investment security regard shortterm investment investment security government fair value debt security determined quoted market price municipal bond price offered financial institution equity security bond determined quoted market price refer note shortterm security maturity investment investment security information security holding purpose total million yen liability n otes account payable shortterm bank loan accrued due due income tax year year since item settled short time period carrying due due year less year year year value approximates fair value cash cash equivalent current portion longterm loan longterm loan note account fair value current portion longterm loan longterm receivabletrade loan based present value total principal interest affiliate discounted estimated interest rate applied similar new shortterm investment investment security loan made longterm loan floating interest hedged interest rate swap agreement accounted loan fixed government municipal bond interest rate fair value longterm loan based bond present value total principal interest cash flow security interest rate swap agreement discounted reasonably estimated maturity interest rate applied similar new loan made total bond payable fair value bond payable based quoted market price thousand u dollar derivative transaction due due year year please refer note derivative transaction due due year less year year year b f inancial instrument extremely difficult determine cash cash equivalent fair value note account thousand receivabletrade million yen u dollar affiliate shortterm investment unlisted equity security investment security government municipal bond quoted market price available extremely dif bond ficult determine fair value financial instrument security included preceding table maturity total shionogi annual report management shionogis business activity shionogis csr activity management system financial corporate information section consolidated financial statement impairment loss fixed asset effective tax rate year ended march fixed asset business use grouped based corresponding differ statutory tax rate following reason management segment product line asset available rent idle asset grouped individually statutory tax rate impairment loss fixed asset year ended march expense deductible income tax purpose summarized follows dividend taxable income tax purpose million thousand amortization goodwill yen u dollar tax credit location use classification inhabitant per caput tax united state business ethical america pharmaceutical difference statutory tax rate overseas product goodwill subsidiary united state exclusive marketing consolidation adjustment sale america right ethical consolidated subsidiary pharmaceutical marketing decrease deferred tax asset due change product right statutory tax rate increase valuation allowance upon concluding agreement concerning antihiv drug viiv loss valuation investment affiliate healthcare ltd viiv located united kingdom company effect organization restructuring considered reallocating management resource u operation found indication impairment marketing right others effective tax rate associated product shionogi inc whollyowned subsidiary united state america sell shionogi also found indication tax effect temporary difference march impairment goodwill due change grouping general gave rise significant deferred tax asset liability prescription drug business u operation result shionogi presented group recognized impairment loss equivalent difference thousand book value recoverable value impaired asset million yen u dollar impairment loss fixed asset year ended march deferred tax asset summarized follows tax loss carry forward million research development yen cost location use classification accrued expense united state inprocess research current liability america development loss revaluation expense investment security compound developing allowance employee pharmaceutical asset bonus provision sale return retirement benefit company concluded future value use existed accrued enterprise tax certain pharmaceutical compound recorded process research development expense included asset valuation allowance result group reduced related carrying value inprocess research development expense included asset recov total deferred tax asset erable value zero recognized impairment loss deferred tax liability unrealized gain security income tax prepaid pension cost income tax applicable company domestic consoli investment security dated subsidiary comprise corporation tax inhabitant tax reserve advanced enterprise tax aggregate resulted statutory tax rate depreciation fixed approximately year ended march asset overseas subsidiary subject income tax total deferred tax liability respective country operate net deferred tax asset shionogi annual report retirement benefit cost sale following table set forth retirement benefit obligation plan cost sale included loss devaluation inventory asset funded status group defined benefit pension million thousand million year ended plan march march respectively thousand million yen u dollar research development expense research development expense included selling general retirement benefit obligation end year administrative expense year ended march fair value plan asset amounted million thousand end year million respectively unfunded status unrecognized actuarial loss loss sale fixed asset unrecognized prior service loss sale fixed asset year ended march cost follows net retirement benefit thousand obligation million yen u dollar prepaid pension cost accrued retirement benefit building structure employee land furniture fixture table include special retirement benefit expense total paid please refer note special retirement benefit expense loss disaster loss disaster year ended march represented component retirement benefit expense year ended estimated amount covered insurance connection march outlined follows disposal inventory damaged fire supplier shionogi inc thousand million yen u dollar company recorded loss disaster connection service cost impact great east japan earthquake year ended march interest cost expected return plan asset litigation settlement amortization actuarial loss litigation settlement principally represents settlement amortization prior service reached shionogi inc lupin ltd cost contribution defined special retirement benefit expense contribution pension plan expense attributable retirement benefit expense incurred retirement benefit expense shionogi inc assumption used accounting defined benefit pension business structure improvement expense plan year ended march follows business structure improvement expense represents cost related reorganization shionogi inc discount rate expected rate return plan asset end fiscal year ended march company subsidiary revised discount rate applied beginning fiscal year result company deter mined change discount rate would significantly affect amount retirement benefit obligation therefore changed discount rate shionogi annual report management shionogis business activity shionogis csr activity management system financial corporate information section consolidated financial statement consolidated statement thousand u dollar carrying value fair value comprehensive income april net change march march following table present analysis comprehensive income year ended march thousand million yen u dollar carrying value table presented amount acquisition cost less accumulated depreciation accumulated net unrealized holding gain impairment loss security fair value march primarily calculated based real amount arising year estate appraisal standard case amount adjusted reclassification adjustment gain loss included net using index method income tax effect related party transaction tax effect principal transaction subsidiary related party total year ended march summarized follows deferred loss gain hedge amount arising year transaction director thousand reclassification adjustment million yen u dollar gain included net income tax effect shunjusha co ltd tax effect rent receivedland office total building translation adjustment rent expensebuilding amount arising year management fee leased reclassification adjustment property gain included net income tax effect shunjusha co ltd directly owned director relative tax effect director company engaged real estate leasing total business percentage voting right owned two people comprehensive income march shunjusha co ltd located chuoku osaka capital amount million thou investment rental property sand million march respectively group owns office building including land lease mainly price related party transaction determined tokyo area reference market value transaction made area rental income net related expense relevant real estate property amounted million thousand outstanding balance connection related party million year ended march rental transaction outlined march income principally recorded net sale rental expense principally recorded cost sale supplementary cash flow information carrying value consolidated balance sheet correspond significant noncash transaction ing fair value property follows october company received share viiv valued million yen million thousand contribution kind carrying value fair value involving transfer equity ownership shionogiviiv healthcare april net change march march lp equitymethod affiliate million yen carrying value fair value april net change march march shionogi annual report summary asset liability former financial data used computation basic net income per unconsolidated subsidiary became newly share diluted net income per share year ended march consolidated subsidiary due acquisition share table summarized follows september company acquired share co thousand million yen u dollar initially consolidated account co consolidated subsid iaries december sixmonth period information used computation ended asset liability included consolidation sum basic net income per share marized follows net income million yen thousand share current asset noncurrent asset weightedaverage number share goodwill common stock outstanding current liability increase common stock noncurrent liability share subscription right minority interest acquisition cost financial data used computation net asset per share cash cash equivalent co march table summarized follows account payable thousand cash disbursement million yen u dollar total net asset amount per share amount deducted total amount per share year ended march net asset follows amount attributable share yen u dollar subscription right total net asset net income amount attributable minority interest total net asset diluted net income net asset used calculation net asset net asset per share cash dividend applicable year thousand share net income per share computed based net income attribut number share used calculation net able shareholder common stock weightedaverage asset per share number share common stock outstanding year diluted net income per share computed based net income attributable shareholder common stock weighted average number common share outstanding year giving effect dilutive potential share common stock issued upon exercise stock option amount per share net asset computed based number share common stock outstanding year end cash dividend per share represent cash dividend proposed board director applicable respective year together interim cash dividend paid shionogi annual report management shionogis business activity shionogis csr activity management system financial corporate information section consolidated financial statement derivative transaction derivative transaction hedge accounting apply information derivative transaction hedge accounting apply omitted since outstanding derivative position qualified hedge accounting derivative transaction hedge accounting applies currencyrelated transaction million yen contract value portion notional transaction principal hedged item notional amount amount one year fair value forward foreign currency exchange contract selling usd forecasted transaction forward foreign currency exchange contract buying usd forecasted transaction currency option selling call option usd forecasted transaction currency option buying put option usd forecasted transaction million yen contract value portion notional transaction principal hedged item notional amount amount one year fair value forward foreign currency exchange contract selling usd forecasted transaction forward foreign currency exchange contract buying usd forecasted transaction currency option buying call option usd forecasted transaction currency option selling put option usd forecasted transaction currency option selling call option usd forecasted transaction currency option buying put option usd forecasted transaction thousand u dollar contract value portion notional transaction principal hedged item notional amount amount one year fair value forward foreign currency exchange contract selling usd forecasted transaction forward foreign currency exchange contract buying usd forecasted transaction currency option selling call option usd forecasted transaction currency option buying put option usd forecasted transaction note fair value calculated based price provided counterparty financial institution currency option contract zerocost option premium received paid shionogi annual report interest raterelated transaction million yen contract value portion notional method hedge accounting transaction principal hedged item notional amount amount one year fair value special accounting treatment interest rate swap shortterm bank pay fixedreceive floating loan longterm debt million yen contract value portion notional method hedge accounting transaction principal hedged item notional amount amount one year fair value special accounting treatment interest rate swap pay fixedreceive floating longterm debt thousand u dollar contract value portion notional method hedge accounting transaction principal hedged item notional amount amount one year fair value special accounting treatment interest rate swap shortterm bank pay fixedreceive floating loan longterm debt since interest rate swap accounted special accounting treatment refer note p fair value included shortterm bank loan longterm debt disclosed note financial instrument segment information geographical information segment information year ended march net sale thousand million yen u dollar group operates single business segment related prescription drug involving research development purchasing manufacturing japan distribution related business prescription drug analy europe sale product evaluation performance group com united kingdom panies performed decision business strategy allocation north america management resource especially allocation research develop united state america ment expense made groupwide basis therefore disclosure segment information year ended march total omitted related information net sale information classified country region information sale product service based location customer main country region amount sale third party one type product included category follows service single segment accounted net europe united kingdom switzerland germany sale consolidated statement income year ended north america united state america march information sale product asia service omitted b property plant equipment balance property plant equipment located japan accounted balance property plant equipment recognized consolidated balance sheet march information property plant equipment geographical segment omitted shionogi annual report management shionogis business activity shionogis csr activity management system financial corporate information section consolidated financial statement information major customer date equity ownership transfer net sale october thousand million yen u dollar related segment customer name name outline transaction including legal form suzuken co ltd pharmaceutical contribution inkind astrazeneca uk limited pharmaceutical viiv received equity ownership jv return shionogi group received share viiv toho pharmaceutical co ltd pharmaceutical outline accounting treatment transfer accounted transfer asset exchange group primarily engaged research development mer share transferee excluding business divestiture based chandising manufacturing marketing ethical pharmaceutical accounting standard business divestiture asbj statement related business december guidance accounting standard accordingly information regarding impairment loss fixed asset business combination accounting standard business divesti amount amortization goodwill remaining balance gain tures asbj guidance december negative goodwill reportable segment march year ended omitted gain exchange million thousand shionogi group recognized difference carrying business combination value equity position jv market value fair value transfer equity ownership shionogiviiv healthcare lp percent equity position viiv gain exchange investment summary equity ownership transfer security name equity ownership transferee viiv healthcare ltd carrying value transferred equity ownership investment security million thousand detail transferred equity ownership shionogi group transferred equity ownership percent shion name corresponding reportable segment ogiviiv healthcare lp equitymethod affiliate prescription drug jv jv established joint venture agreement shionogi group viiv united kingdom income associated transfer equity ownership reported consolidated statement income reason transfer equity ownership fiscal year ended march follows shionogi group established jv purpose developing thousand million yen u dollar marketing product development focused hiv integrase net sale inhibitor dolutegravir generic name shionogi code dtg operating income related product including combination dtg inte ordinary income grase inhibitor however combination treatment various drug expected mainstream treating hiv therefore management jv subsequent event dtg single asset would face difficulty addition following distribution retained earnings company shionogi group acquired sciele pharma inc currently shionogi reflected accompanying consolidated financial inc jv necessary establishing base sale statement year ended march approved united state originally expected jv formed shareholder meeting held june million thousand furthermore shionogi inc marketing model aligned yen u dollar selling hiv drug accordingly changing circumstance time cash dividend us per share led shionogi group initiate discussion creating new framework acquisition clinical trial data required ndas completed october submission ndas dtg planned shionogi group concluded agreement transferred equity jv viiv exchange per cent state viiv information purpose ndas dtg submitted december shionogi annual report independent auditor report board director shionogi co ltd audited accompanying consolidated financial statement shionogi co ltd consolidated subsidiary comprise consolidated balance sheet march consolidated statement income comprehensive income change net asset cash flow year ended summary significant accounting policy explanatory information expressed japanese yen management responsibility consolidated financial statement management responsible preparation fair presentation consolidated financial statement accordance accounting principle generally accepted japan designing operating internal control management determines necessary enable preparation fair presentation consolidated financial statement free material misstatement whether due fraud error auditor responsibility responsibility express opinion consolidated financial statement based audit conducted audit accordance auditing standard generally accepted japan standard require plan perform audit obtain reasonable assurance whether consolidated financial statement free material misstatement audit involves performing procedure obtain audit evidence amount disclosure consolidated financial statement procedure selected depend auditor judgment including assessment risk material misstatement consolidated financial statement whether due fraud error purpose audit consolidated financial statement express opinion effectiveness entity internal control making risk assessment auditor considers internal control relevant entity preparation fair presentation consolidated financial statement order design audit procedure appropriate circumstance audit also includes evaluating appropriateness accounting policy used reasonableness accounting estimate made management well evaluating overall presentation consolidated financial statement believe audit evidence obtained sufficient appropriate provide basis audit opinion opinion opinion consolidated financial statement referred present fairly material respect consolidated financial position shionogi co ltd consolidated subsidiary march consolidated financial performance cash flow year ended conformity accounting principle generally accepted japan convenience translation reviewed translation consolidated financial statement u dollar presented convenience reader opinion accompanying consolidated financial statement properly translated basis described note june osaka japan shionogi annual report management shionogis business activity shionogis csr activity management system financial section corporate information shionogi group directory august major business location major consolidated subsidiary head office branch office shionogi pharma chemical co ltd head office ebisuno hiraishi kawauchicho tokushima japan doshomachi chome chuoku osaka japan tel tel fax shionogi analysis center co ltd tokyo branch office mishima chome settsu osaka japan shionogi shibuya bldg shibuya chome tel shibuyaku tokyo japan saishin igaku co ltd tel shionogi doshomachi bldg doshomachi chome chuoku osaka nagoya branch office japan sky oasis sakae shinsakaemachi chome tel nakaku nagoya aichi japan shionogi techno advance research co ltd tel futabacho toyonaka osaka japan fukuoka branch office tel shin kbc bldg nagahama chome chuoku shionogi general service co ltd fukuoka city fukuoka japan shionogi doshomachi bldg doshomachi chome chuoku osaka tel japan sapporo branch office tel nissay sapporo bldg kitasanjonishi chome taiwan shionogi co ltd chuoku sapporo hokkaido japan f sec nanking east road taipei taiwan tel tel development office shionogi inc global development office campus drive florham park nj usa f hankyu terminal bldg shibata chome tel kitaku osaka japan ezose science inc tel riverside drive pine brook nj usa laboratory tel shionogi pharmaceutical research center co pharmaceutical technology holding limited futabacho chome toyonaka osaka japan silvercord tower canton road tel tsim sha tsui kowloon hong kong tel shionogi innovation center drug discovery kita nishi kitaku sapporo hokkaido japan shionogi limited tel shortlands hammersmith london w da united kingdom tel plant beijing shionogi pharmaceutical technology limited settsu plant room level tower china central place jianguo road mishima chome settsu osaka japan chaoyang district beijing tel tel kanegasaki plant moriyama nishine kanegasakicho isawagun iwate japan tel administration office kuise site kuise terajima chome amagasaki hyogo japan tel aburahi facility gotanda kokacho koka shiga japan tel distribution center shionogi osaka distribution center mitsubishi logistics corporation ibaraki distribution center fujinosato chome ibaraki osaka japan tel shionogi tokyo distribution center mitsubishi logistics corporation misato distribution center hikoe chome misato saitama japan tel overseas office outside japan shionogi co ltd taipei office f sec nanking east road taipei taiwan tel shionogi co ltd shanghai office far east international plaza f xian xia road shanghai people republic china tel shionogi annual report corporate information march company name shionogi co ltd number employee consolidated established march category business marketing manufacturing drug incorporated june type business manufacturing distribution paidin capital million pharmaceutical diagnostic reagent website httpwwwshionogicojpindex_ehtml medical device etc head office doshomachi chome chuoku fiscal yearend march osaka japan net sale consolidated million tel year ended march fax stock security listing tokyo transfer agent sumitomo mitsui trust bank limited common stock authorized share stock transfer agency department issued share kitahama chome chuoku number shareholder osaka japan major shareholder number percentage name share total share thousand master trust bank japan ltd trustee sumitomo life insurance company japan trustee service bank ltd trustee jp morgan chase bank nippon life insurance company ssbt od omnibus account treaty client japan trustee service bank ltd trustee sumitomo mitsui trust bank ltd ii retirement benefit sumitomo mitsui banking corporation sumitomo mitsui banking corporation state street bank trust company mellon bank na agent client mellon omnibus u pension note company hold share treasury stock however shareholding included list top shareholder percentage total share calculated proportion share total number issued share less treasury stock stock price range trading volume tokyo stock exchange monthly stock price range ncommon stock price range yen topix price index close monthly trading volume million share shionogi annual report annual report printed japan vegetable oil ink fsc certified paper